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Abstract 
Microorganisms and plants have evolved to produce a myriad array of natural 
products that are of biomedical importance. One group of valuable natural products is 
polyketides, which are known to be antiviral, antibacterial, and anticancer. In my first 
project, I attempted to develop an efficient strategy for cloning and characterizing 
Type III PKS genes that are likely responsible for the synthesis of novel natural 
products from Eucalyptus species. Nested degenerate primers were designed and a 
total of 94 clones and 27 clones were sequenced from the cDNA libraries created 
from the leaves of E. camaldulensis and E. robusta, respectively. Five unique putative 
Type III PKSs genes were identified. Two full-length genes were cloned and the 
biochemical characterization of these genes indicated their functions.   
In my second project, I attempted to develop a synthetic biology approach for 
natural product discovery. Investigation into the unknown compounds synthesized by 
actinomycetes may lead to the discovery of novel chemotherapeutic agents. As proof 
of concept, one cryptic pathway from Streptomyces griseus, containing a PKS/NRPS 
hybrid gene, was chosen as a model system. To decipher this cluster, I have been 
attempting to develop a new strategy based on our recently developed “DNA 
assembler” method.  By using this approach, the gene cluster was modified by 
adding different constitutive promoters in front of each gene. RT-qPCR was 
employed to track expression on the transcription level.  HPLC and LC-MS were 
used to detect the products. A potential product was detected and further 
characterization is in progress. 
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Chapter 1 Overview of Natural Products Discovery 
1.1 Importance of natural products biosynthesis 
1.1.1 Significant source for medicinal compounds 
Over the past 10 years, there has been a resurgence of interest in the investigation 
of natural products as a source of new drugs.  Around 78% of antibacterial or 
anticancer drugs are natural products or have been derived from natural products (1).  
The data shown in Annual Reports of Medicinal Chemistry highlight the invaluable 
role that natural products have played in the drug discovery process related to all 
disease types (2).  Although many effective drugs have been discovered, the need for 
new therapeutic agents remains due to the increasing antibiotic resistance to existing 
drugs and the recent threat of bioterrorism. Natural products are the most significant 
source for modern medicine discovery (3). Up to date, only a small portion of the 
natural products have been discovered and well-characterized. The Streptomyces 
species alone is predicted to produce as many as 150,000 natural products, while only 
3% have been characterized (4). With the development of novel biotechnologies and 
expanding understanding of the biology world, the field of natural products discovery 
has become an active field of investigation. For example, many bioactive natural 
products are synthesized by non-ribosomal peptide synthetases (NRPS) and 
polyketide synthases (PKS) (5,6). 20 out of 7000 polyketides known to exist have 
been commercialized as medicines, which has a “hit rate” that is already two orders 
higher than other classes of chemicals (7). Therefore, investigation into the unknown 
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compounds synthesized by these two classes of enzymes may lead to the discovery of 
a variety of novel chemotherapeutic agents. 
      
Erythromycin              Aflatoxin B1             Aloesone 
S. erythrea                 A. flavus              R.palmatum 
   
Taxol                         L-DOPA 
Taxus brevifolia                   Mucuna sp. 
Figure 1.1 Natural products discovered from bacteria, fungi and plants. 
1.2 Common sources of natural products 
1.2.1 Plants as a source of natural products 
Medicinal plants have been used for thousands of years in the treatment of 
numerous ailments (8). Modern analytical techniques identified the bioactive 
compounds in plant extracts and approximately 25% of today’s medicines are derived 
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from plant natural products (9), including many highly successful drugs such as the 
best breast cancer therapy Taxol (paclitaxel) (10) and anti-Parkinson’s treatment 
L-DOPA. Plant-derived polyketides such as curcuminoids (curcumin) and flavonoids 
(genistein, quercetin, resveratrol) are well-known complementary therapies, with a 
growing body of evidence vis-à-vis their usefulness as anti-inflammatory and 
anti-cancer agents (11,12). For example, the phloroglucinol components of bioactive 
plants were generally discovered by analyzing organic solvent fractions of plant 
materials. Searching databases of scientific literature uncovered a number of target 
plants across a wide range of species, and in nearly all cases, chemical 
characterization of the phloroglucinol natural products was not followed by 
subsequent characterization of the producing enzymes. 
Eucalypts produce a wide variety of acylphloroglucinol compounds which may 
be formylated or acylphloroglucinol-terpene adducts (e.g. euglobals and macrocarpals 
(13)). Eucalypt polyketide natural products are known to be antiviral, antibacterial, 
anticancer, and cariostatic (inhibit the growth of bacteria that cause tooth decay), and 
Eucalypts have been used by the Aboriginal people of Australia for the treatment of 
colds, influenza, toothache, snakebites, fevers, and other ailments (13).  
4 
 
 
Figure 1.2 Polyketides and polyketide-terpene adducts from E. robusta. 
1.2.2 Fungi as a source of natural products 
Fungi have existed on earth for at least one thousand million years, and they have 
exploited and evolved secondary metabolism for the production of bioactive 
compounds (14). These compounds include toxins such as α-amanitin, the toxic 
principal component of Amanita phalloides (death cap), vomitoxin (deoxynivalenol) 
produced by the Fusaria family of plant pathogens and aflatoxin B1 produced by 
Aspergillus species. Fungi also produce potent psychoactive compounds such as 
muscimol, psilocybin and xenovulene A, pharmaceuticals such as the β-lactams and 
the statin lovastatin. These compounds illustrate the utility and diversity of chemical 
structures produced by fungi, and the diverse biosynthetic potential of these 
organisms. Among all the compounds produced by fungi, a wide variety of 
polyketides with diverse structures, such as orsellinic acid, lovastatin, and aflatoxin 
can be found as well (14). Most of these compounds are bioactive and usually 
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pharmacologically useful. For example, lovastatin which is produced by Aspergillus 
terreus, can lower the cholesterol by inhibiting the rate-limiting enzyme in cholesterol 
synthesis. Fungi can inhabit almost all known environments on earth — from 
temperate soils and forests to deserts and from oceans to tropical rain forests. Thus, it 
is not surprising that they can produce numerous medicinal natural products (15).  
1.2.3 Bacteria as a source of natural products 
Bacteria represent a rich source of natural products as well. Type II PKS are 
found in bacteria exclusively, which can synthesize a variety of polyketides, such as 
oxytetracycline from Streptomyces rimosus, and daunorubicin from Streptomyces 
peucetius (16). Bacteria produce many different tetracyclines, one of the most 
important classes of antibiotics, and anthracyclines, a potent class of anticancer 
compounds which includes daunorubicin. Actinomycetes are a group of bacteria 
capable of producing numerous natural products. The Streptomyces species alone is 
predicted to produce as many as 150,000 natural products. Most of them are 
secondary metabolites. For example, 20 secondary metabolite biosynthesis pathways 
have been revealed from actinomycete Streptomyces coelicolor A3(2) [18] and the 
industrial actinomycete Streptomyces avermitilis [19]. Another example is 
Streptomyces griseus, from which genomic sequence, 34 secondary metabolite 
pathways have been found (17). These gene clusters reveal the high possibility of 
discovery of new natural products. 
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1.2.4 Cryptic pathways as a source of natural products 
The recent increase and availability of whole genome sequences have revised our 
view of the metabolic capabilities of microorganisms. A large number of orphan 
biosynthesis pathways have been identified by bio-informatics study of these data. 
Cryptic biosynthetic pathways are gene clusters for which the encoded natural product 
is unknown or the pathway is silent and the product cannot be detected under general 
growth conditions. It is worthy to note that the number of cryptic pathways coding for 
putative natural products far outnumbers the number of currently known metabolites 
for a given organism. Thus, cryptic pathways serve as an enormous source for natural 
products discovery. 
Since the genomic sequencing projects are mostly focused on bacteria and fungi, 
the cryptic pathways related to valuable secondary metabolites are often revealed 
from the bacteria and fungi genome database. For example, Streptomyces coelicolor 
was known to produce only 4 secondary metabolites (18), the genome analysis 
revealed 18 additional cryptic biosynthetic pathways. It is intriguing to note that this 
is not a particular case because analysis of other microbial genomes originating from 
Myxobacteria, cyanobacteria and filamentous fungi showed the presence of a 
comparable or even larger number of cryptic pathways (19,20). The discovery of 
these numerous pathways represents a treasure trove, which is likely to grow 
exponentially in the future, uncovering many novel and possibly bio-active 
compounds. The few natural products that have been correlated with their orphan 
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pathway are merely the tip of the iceberg, whilst plenty of metabolites await discovery 
(21).  
1.3 Technologies for natural products discovery and identification 
1.3.1 Genome mining 
Genome mining has been used in various fields to describe the exploitation of 
genomic information for the discovery of new processes, targets, and products. 
Genomics has resulted in the deposition of a huge quantity of DNA sequence data 
from a wide variety of organisms in publicly accessible databases. This information 
can be exploited to generate new knowledge in several areas relevant to medicinal 
chemistry including the identification and validation of new drug targets in human 
pathogens, and the discovery of new chemical entities (19). The concept of exploiting 
genomic sequence data for the discovery of new natural products has emerged from 
the rapid expansion in knowledge of the genetic and biochemical basis for secondary 
metabolite biosynthesis, particularly in microorganisms, in the 1980s and 1990s (5).  
Large quantities of genomic sequence data have accumulated in public databases. 
Those of plants and microorganisms, containing numerous genes encoding proteins 
are likely to participate in the assembly of structurally complex bioactive natural 
products but not associated with the production of known metabolites. Therefore, they 
become invaluable as they shed light on the discovery of novel drugs.  
Analysis of the complete genome sequence of the model actinomycete S. 
coelicolor A3(2) (18) and the industrial actinomycete S. avermitilis (22) have 
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facilitated the prediction of structural features of natural products. For example, the 
genome mining of these two bacteria revealed 20 secondary metabolite biosynthetic 
gene clusters, many of which have not been characterized yet. Another example is the 
genome sequence of S. griseus, which revealed 34 secondary metabolites pathways 
and only six of them have been characterized (17). All these information offers the 
researchers a big chance to discover novel high value compounds. 
1.3.2 Metabolic engineering and pathway engineering 
Metabolic engineering is an emerging field of academic research and industrial 
practice with the goal of engineering pathways to either produce value-added 
molecules or degrade harmful compounds in a simple, effective and advantageous 
process (23). It is broadly defined as using recombinant DNA technology to improve 
cellular activities.  Specifically, metabolic engineering includes identification of 
metabolic pathways, elucidation of regulatory mechanisms, metabolic flux analysis, 
metabolic control analysis, identification of inter- or intra- cellular transport 
mechanisms, and discovery and manipulation of biosynthetic pathways.  This area is 
particularly important to natural products biosynthesis because it offers ways to 
optimize the native producer to increase production, enable the heterologous 
expression of a pathway, and balance metabolic flux to maximize production of 
desired compound, as well as produce novel chemicals and pharmaceuticals. 
Applying metabolic engineering to establish metabolic pathways that are able to 
channel carbon flow to a desired product at a high yield requires careful 
considerations.  Four key elements are normally included: (i) direct and optimize the 
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primary metabolic pathway flow to the target product, including removal of rate 
limiting steps, transcriptional and allosteric regulation; (ii) genetically block 
competing branch pathways; (iii) modify secondary metabolic pathways to enhance 
energy metabolism and availability of required enzymatic cofactors; and (iv) remove 
detrimental side-products. For example, hydrocortisone, an important starting material 
for steroidal drug synthesis, can be synthesized from glucose in yeast by metabolic 
engineering (24). Another example is to enhance the production of 
6-deoxyerythronolide B (the polyketide precursor of erythromycin) in the 
heterologous host E. coli to the level of the native producer through metabolic 
engineering (27). As for polyketides, the availability of acyl-CoA is a major obstacle 
in heterologous host as in E. coli or S. cerevisiae, the amounts of propionyl-CoA and 
(2S)-methylmalonyl-CoA are low. Pathways that can use propionate and 
methylmalonate to produce these CoAs were introduced to the heterologous host, 
which resulted in an increase in the final products (25,26).  
1.3.3 Heterologous expression 
Natural products show great promise as medicinal agents. Most of them typically 
act as secondary metabolites of microbial, and some are synthesized by an 
evolutionarily related but architecturally diverse family of multifunctional enzymes. A 
principal limitation for fundamental biochemical studies of these modular 
megasynthases, as well as for their applications in biotechnology, is the challenge 
associated with manipulating the natural microorganism that produces a polyketide of 
interest. For example, they may have strict environmental requirements for growth or 
10 
 
cannot be cultured readily (23). Host organisms may also have a complicated or 
multi-stage growth profile, which may result in little production of a target compound. 
To ameliorate this limitation, several genetically tractable microbes, such as E. coli, B. 
subtilis, S. coelicolor, S. lividans and S. cerevisiae have been developed as 
heterologous hosts for natural product biosynthesis (27). The genes responsible for 
natural product synthesis can be over-expressed heterologously.  
Over the past decade, the study of bioactive natural product biosynthesis has 
benefited significantly from the incorporation of heterologous tools. Compared to 
native producers, heterologous hosts have several advantages such as ease to operate, 
simple growth conditions, excellent fermentation protocols, and abundant genetic 
manipulation tools (23).  
Heterologous expression of polyketides is particularly important as many are 
produced in actinomycetes or plants that often suffer from slow growth rates. 
Reconstitution of polyketide biosynthesis in heterologous hosts demands that large 
multienzyme assemblies be functionally expressed, their posttranslational 
modification be adequately met, their substrates be available in vivo in reasonable 
quantities, and the producer cell be protected against the toxicity of the biosynthetic 
products. Already, heterologous expression of Type I and Type II PKSs has been 
achieved in E. coli to produce the antibiotic erythromycin (28) and plant flavonoids 
(29). In addition, unnatural substrates have been fed into a heterologous host for Type 
III PKS, which resulted in combinatorial biosynthesis of new medicinal natural 
products (30).  
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1.3.4 Techniques used to activate cryptic pathways 
Analyses of the >500 microbial genome sequences currently in the 
publicly-accessible databases have revealed numerous examples of gene clusters 
encoding enzymes similar to those known to be involved in the biosynthesis of many 
important natural products (31). Examples of such enzymes include nonribosomal 
peptide synthetases (NRPSs), polyketide synthases (PKSs) and terpene synthases 
(TSs), as well as enzymes belonging to less thoroughly investigated families. Many of 
these gene clusters are hypothesized to assemble novel natural products. Numerous 
novel metabolites have been discovered as the products of such so-called ‘‘cryptic’’ 
or ‘‘orphan’’ biosynthetic gene clusters and several recent reviews have described 
these discoveries (19,21). The various approaches for discovery of the metabolic 
products of cryptic biosynthetic gene clusters are summarized in Figure 1.3. 
 
Figure 1.3 Techniques used to activate cryptic pathways 
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At the beginning of every discovery of the natural product of an orphan pathway 
and the capability to predict the corresponding structure, significant progress needs to 
be made in the understanding of biosynthetic pathways (21). With this accumulated 
knowledge, combined with the advanced state of bio-informatics, it is nowadays 
possible to reasonably predict the product of an orphan biosynthetic pathway. 
Techniques usually used to active the cryptic pathways include: i) prediction of 
physicochemical properties (32); ii) genomisotopic approach (33); iii) in vitro 
reconstitution approach (34); iv) biosynthetic gene inactivation/comparative 
metabolic profiling approach (35); v) heterologous gene expression/comparative 
metabolic profiling approach (36); vi) activation of silent clusters by manipulation of 
regulatory genes (20). 
1.3.5 Synthetic biology approaches 
The term synthetic biology did not obtain many popularity when it first appeared 
in the literature in late 1970’s (37), which was used to describe bacteria that had been 
genetically engineered using recombinant DNA technology.  At the beginning of last 
century, synthetic biology was again introduced, and quickly became popular, to refer 
to the design and construction of new biological components, such as enzymes, 
genetic circuits, and cells, or the redesign of existing biological systems (38-40).  
The field of synthetic biology lies at the interface of many different biological 
research areas, such as functional genomics, protein engineering, chemical biology, 
metabolic engineering, systems biology, and bioinformatics. Not surprisingly, 
synthetic biology means different things to different people, even to leading 
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practitioners in the field (41).  The fundamental idea behind synthetic biology is that 
any biological system can be regarded as a combination of individual functional 
elements, a limited number of which can be recombined in novel configurations to 
modify existing properties or to create new ones (42).  The element that 
distinguishes synthetic biology from traditional molecular biology and cellular 
biology is the focus on the design and construction of core components that can be 
modeled, understood, and tuned to meet specific performance criteria, and the 
assembly of these smaller components into larger integrated systems that solve 
specific problems (43).  As a broad field, the successful applications of synthetic 
biology make it an invaluable tool for natural products discovery, such as synthesis of 
proteins that do not exist in nature, design and engineering of signaling and metabolic 
pathways, and rebuilding of new organisms.  
 In a further level of complexity, the modular nature makes synthetic biology very 
useful for engineering signaling and metabolic pathways and prompts the discovery of 
natural products.  Although de novo synthesis of a biochemical pathway is possible 
using the DNA synthesis tools, most efforts focus on construction and optimization of 
an existing biochemical pathway either in a native or a heterologous host.  Pathway 
engineering can be designed rationally by mixing and matching well-known, modular 
parts and modulating gene expression through various control mechanisms. However, 
the design at the pathway level is not only concerned with including the necessary 
biological parts such as promoters, genes, and proteins, but also with optimizing the 
expressed functionality of those parts. Failure to balance the flux in the synthetic 
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pathway will result in a bottleneck and the accumulation of intermediates (44). One 
way to balance the flux is through transcription optimization of the various genes in 
the pathway. By fusing a library of promoters to the various enzymes in the 
isoprenoid production pathway, Pitera and coworkers have managed to engineer a 
flux-balanced pathway with improved yield and reduced metabolic burden (44). 
These well-characterized families of transcription regulators have emerged as 
powerful tools in metabolic engineering as they allow rational coordination and 
control of multigene expression, thereby decoupling pathway design from 
construction (45).  
The concept of synthetic biology is relatively broad, and the development and 
characterization of individual components continue to increase.  With our increasing 
understanding in genomics and proteomics and with the development of more 
powerful techniques for system design, synthesis and optimization, a rapid growth in 
the capabilities of synthetic systems with a wide-range of applications will be seen in 
the near future.   
1.4 Polyketides as natural products 
1.4.1 Polyketides 
Polyketides are a diverse group of natural products with important applications in 
medicine and industry. It can be found in a variety of organisms including plants, 
fungi, and bacteria, in which they are produced by polyketides synthases (PKS) which 
polymerize acyl-Coenzyme As (CoA) in a fashion similar to fatty acid synthesis (46). 
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Usually, they are not strictly required for the growth, development, or reproduction of 
their host organisms, but they perform an important role in both industrial chemical 
synthesis and drug discovery. Polyketides are structurally varied and in turn have a 
broad range of different biological activities. The diversity of natural polyketides 
comes both from the priming acyl-CoAs and elongating acyl-CoAs used, and the 
chemical transformations occurring after polyketide synthesis. Polyketide natural 
products are known to have antiviral (47), antibacterial (48), and anticancer (49) 
activities.  Therefore, they are widely used in clinical trials and industry (7). For 
example, a number of plant species produce a wide variety of phloroglucinol 
derivatives. Phloroglucinol natural products may be monomeric, dimeric, trimeric, or 
modified by prenylation or O- or C-glycosylation. These varied phloroglucinols have 
many known bioactivities including anti-feedant, antifungal, antibiotic, antitumor, 
anti-malarial, antidepressant, anti-dementia, antiviral, antioxidant, and 
anti-inflammatory or anti-allergy activities. 
1.4.2 Polyketide synthases 
Polyketide natural products have diverse structures, many of which are clinically 
valuable drugs. They are derived from acetate and other short carboxylic acids by 
sequential decarboxylative condensations in a fashion similar to fatty acid 
biosynthesis, and this process is catalyzed by polyketide synthases (PKSs). There are 
three types of PKSs known to date.  Type I and type II PKSs are microbial enzymes, 
whereas type III PKSs are mainly found in plants (50).  
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Type I PKSs, a group which is further sub-divided into iterative (Figure 1.2A) 
and modular type I PKSs (Figure 1.2B), are responsible for the biosynthesis of 
complex, largely reduced polyketides, such as macrolides (erythromycin and 
avermectin), polyethers (monensin and tetronasin), polyenes (candicidin and nystatin), 
and hybrid peptide-polyketide natural products, such as bleomycin, epothilone and 
rapamycin. Type I PKSs are made up of a single, very large multi-domain protein that 
is structurally organized into modules. Type II PKSs are multi-enzyme systems as 
well, but each domain contained in Type II PKSs acts as a free-standing enzyme 
(Figure 1.2C). Type III PKSs are small, homodimeric enzymes and represent a single 
domain (Figure 1.2D). One to six functional modules can be assembled into one 
individual PKS, each consisting of several distinct active sites, for each enzymatic 
step. A module is in charge of one cycle of polyketide elongation and the associated 
modifications. The order of modules in the PKS enzyme indicates the sequence of 
biosynthetic events. Variations of domains within the modules afford the structural 
diversity observed in the resultant polyketide products. The growing polyketide 
intermediates are tethered to the PKSs via a thioester linkage to the 
4'-phosphopantetheine prosthetic group of the acyl carrier protein (ACP) domain 
during the entire elongation process. Thus, the three core domains: β-ketoacyl 
synthase (KS), acyltransferase (AT), and ACP, catalyze the C-C elongation, and the 
accessory domains, such as ketoreductase, dehydratase, enoyl reductase and 
methyltransferase, control the modifications of the growing polyketide intermediates. 
Once the growing polyketides chain reaches its full length, it is released from the PKS 
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enzyme by a thioesterase (TE) domain or a discrete amidase to yield the final products 
(51). 
 
 
Figure 1.4 Representative structures of PKS enzymes. (A) Iterative Type I PKS, (B) 
Non-iterative, modular Type I PKS, (C) minimal Type II PKS, and (D) Type III PKS. 
Domain abbreviations: KS, ketosynthase; AT, acyltransferase; ACP, acyl-carrier protein; KR, 
ketoreductase; DH, dehydratase; TE, termination (52). 
1.5 Project overview 
Microorganisms and plants have evolved to produce a myriad array of natural 
products that are of biomedical importance (1). This thesis focuses on discovery and 
characterization of novel natural products. As polyketides represent a huge class of 
structurally diverse natural products, I chose PKSs as my targets. Throughout my 
thesis, I have applied the above-mentioned laboratory techniques to natural products 
biosynthesis and discovery, including: i) use of genome-mining to identify a target 
cryptic gene cluster, SGR810-815, from the sequenced genome of S. griseus; ii) use 
of synthetic biology to activate the cryptic SGR810-815 gene cluster from S. griseus 
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in S. lividans, iii) discovery of novel Type III PKS enzymes by mining biodiversity of 
medicinal plants;4) heterologous expression of Type III PKS genes in E. coli. 
Chapter 2 describes the characterization of the Type II PKS enzyme EC2 from 
Eucalyptus camaldulensis. The overall goal is to identify new Type III PKS enzymes 
from bioactive plants. A PCR-based screening method for Type III PKS genes 
discovery was created and validated. Two Eucalyptus species were chosen as initial 
targets for Type III PKS discovery.  The leaves of Eucalyptus robusta were used to 
produce an anti-malarial medicine (13).  Eucalyptus camaldulensis was chosen as 
the second target species.  Nested degenerate primers were designed based on 14 
different plant Type III PKS and were validated by amplifying PKSs from Hypericum 
perforatum.  A total of 94 clones and 27 clones were sequenced from the cDNA 
libraries created from the leaves of E. camaldulensis and E. robusta, respectively.  
Five unique putative Type III PKSs genes were identified based on the screening 
method. To further validate the cloned putative Type III PKS fragments, RACE-PCR 
(rapid amplification of cDNA ends-polymerase chain reaction) was used to clone the 
full-length gene.  One full-length gene was successfully cloned. The biochemical 
characterization of this gene led to the identification of one novel Type III PKS. 
However this gene shares a high sequence identity (75%) with chaclone synthase 
(CHS) from Medicago sativa. The generation of naringenin from 4-coumaroyl-CoA 
and malonyl-CoA was confirmed. Also, different CoAs as start units were tested to 
explore the novelty of this enzyme. However, it turned out to be a CHS and no new 
reaction was detected.  
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Chapter 3 reports my progress on the development of synthetic biology 
approaches to activate a cryptic pathway SGR810-815 from S. griseus. As many 
bioactive natural products are synthesized by non-ribosomal peptide synthetases 
(NRPS) and polyketide synthases (PKS) (5,6), investigation into the unknown 
compounds synthesized by these two classes of enzymes may lead to the discovery of 
novel chemotherapeutic agents. Our motivation is to develop an efficient approach to 
decipher the cryptic natural product biosynthetic pathways. As proof of concept, one 
cryptic pathway from S. griseus (17), SGR810-815, containing a PKS/NRPS hybrid 
gene, was chosen as a model system.  BLAST search indicates that the PKS/NRPS 
gene shares high sequence identity (63%) with the one from the heat-stable antifungal 
factor (HSAF) biosynthetic gene cluster (53) and 70-80% sequence homology with 
the recently characterized frontalamide gene cluster (54). However, the nature of the 
natural product encoded by the target pathway is still not clear. To decipher this 
cluster, I have been attempting to develop a new strategy based on our developed 
“DNA assembler” method (55). In this method, all of the resulting DNA products 
were co-transformed into S. cerevisiae for assembly into a single DNA molecule in 
one step based on the yeast homologous recombination mechanism. Verified 
constructs were integrated into the genome of S. lividans for heterologous expression.  
By using this approach, gene clusters can be easily assembled and modified.  Thus, 
three modified constructs were assembled and used as controls for the 
characterization of the cluster. RT-PCR and SDS-PAGE were employed to track 
expression both on the transcription and translation levels. HPLC and LC-MS were 
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used to detect the products. Preliminary data showed the formation of new 
compounds. In parallel, two more plasmids were constructed, which contained one or 
six artificial operons to regulate the production of target product. These two 
constructs will be evaluated in the near future. Consequently, construction of artificial 
operons should be able to improve gene expression, which in turn increases the 
product yield.  
1.6 Conclusions and outlook 
As a valuable class of compounds for drug discovery and generation of industrial 
chemicals, natural products have drawn increasing attentions with the development of 
new biotechnology tools. Polyketides produced by microorganisms show an 
extraordinary structural diversity and represent a huge collection of biologically active 
compounds. Polyketides are synthesized by polyketide synthases. As a class of 
multifunctional enzymes, they create remarkable structural complexity and diversity 
by varying the building blocks of different elongation stages.  
Type III PKSs are comprised of mono-functional enzymes. Because of its simple 
structure and relative short sequence, it is easier to study. However, due to the lack of 
genomic information from plants, it is hard to discover novel Type III PKS from 
bioactive plants. Insert a few sentences to summarize your key findings.  
The natural products from actinomycetes represent another type of attractive 
compounds. With the rapid development of DNA sequencing techniques and publicly 
assessable genomic sequence data, the deciphering of cryptic biosynthetic pathways 
should lead to the discovery of novel high value compounds. By studying one cryptic 
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pathway from Streptomyces griseus, I have been able to produce the potential product 
from the pathway by applying synthetic biology approach, which contains pathway 
engineering and assembly that would be talked in detail in Chapter 3. 
In general, the new synthetic biology approach I plan to develop will enable rapid 
introduction of gene deletions and insertions into the pathway, which will help to 
study the mechanism of a biosynthetic pathway. In addition, this approach can be 
used to balance pathway gene expression, optimize metabolic flux, and generate new 
compounds. Overall, this genomics-driven, synthetic biology enabled method offers 
the ultimate versatility and flexibility in characterizing and engineering natural 
product biosynthetic pathways, which will greatly facilitate the exploration of the 
genomic information and the discovery of valuable natural products. 
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Chapter 2 Discovery of Novel Type III PKS from Bioactive 
Plants 
2.1 Introduction 
Polyketides found in plants include chalcones and stilbenes. The enzymes 
responsible for the biosynthesis of these polyketides are classified as polyketide 
synthases (PKSs). In most cases, the production of polyketide metabolites in plant 
species has been traced to the activity of Type III PKSs. The Type III PKSs are the 
smallest PKS and essentially represent a single domain of the multi-domain Type I or 
Type II PKS enzymes, mostly the KS domain. They usually form homodimers and the 
two independent active sites of the homodimer act iteratively, catalyzing the 
sequential condensation of two-carbon acetate units derived from a malonate thioester 
into a growing polyketide chain (1). Although they are simple in structure, they can 
produce a variety of bioactive aromatic compounds with single or multi-ring 
structures. Type III PKSs were traditionally associated with plants but recently 
discovered in a number of bacteria and filamentous fungi (2). Type III PKS were 
thought to be diverged from bacterial β-ketoacyl-acyl-carrier-protein synthase III 
(KAS III) enzymes (3). Alkylresorinol synthases of bacterial and fungi are thought to 
be the ancestors of Type III PKS enzymes, while chalcone synthase evolved from 
plants after the Type III PKS was transferred about 450 million years ago from 
primitive cyanobacteria (3).  
Medicinal plants have been used for thousands of years in the treatment of 
numerous diseases and drug discovery (4). Approximately 25% of today’s medicines 
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are derived from plant natural products such as the Taxol used in breast cancer 
therapy (5) (Figure 2.1). Overall, natural products from plants include terpenes, 
alkaloids, lignans, and polyketides. Many well-known complementary therapies, such 
as curcuminoids (curcumin) and flavonoids (genistein, quercetin, resveratrol) were 
occupied a large portion of the natural products discovered from bioactive plants. 
They were usually extracted from plant extracts using newly-developed analytical 
techniques (6,7). For example, the phloroglucinol components of bioactive plants 
were generally discovered by analyzing organic solvent fractions of plant materials 
(8). Phloroglucinols itself and its derivatives are smooth muscle relaxants and serve as 
antispasmodic in clinical use. It is sold in Europe under the names Spasfon and 
Spasfon Lyoc. The one used in industry and medicine is synthesized chemically; 
however, it has received little attention for bio-production. Searching databases of 
scientific literature uncovered a number of target plants across a wide range of species, 
we found phloroglucinols and its derivatives were isolated from Acacia arabica and 
Euclyptus kino and others (8). In nearly all cases, chemical characterization of the 
phloroglucinol natural products was not followed by subsequent characterization of 
the producing enzymes. So far, only two acylpholoroglucinol-producing enzymes 
from plants have been studied, isovalerophenone synthase from Humulus lupulus (9) 
and PKS1 from Hypericum perforatum (10). Thus, the genetic material of known 
phloroglucinol or its derivatives producing plants provide rich sources of 
uncharacterized phloroglucinol synthase enzymes. 
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The well-studied plant Type III PKSs are the chalcone synthases (CHSs), which 
are involved in the synthesis of precursors of certain pigments. A large number of 
CHS family enzymes have been discovered and characterized (2). Based on these 
CHSs, it may be possible to isolate new Type III PKS from bioactive plants, such as 
enzymes that are capable of synthesizing phloroglucinol or acylphloroglucinol.  
The goal of this project is to create a PCR-based screening method using 
degenerate primers to identify novel Type III PKS, especially phloroglucinol synthase, 
from bioactive plants. If not, an enzyme with previously uncharacterized substrate 
specificity or new intermediates or products will be a valuable discovery as well. In 
this method, degenerate primers were used as probes to mine the plant genetic 
materials. Therefore, a validation of the degeneracy of the primers needs to be tested 
first, to confirm the efficiency of our degenerate primers. Once this method is 
validated, future discovery of new Type III PKS can be processed and 
characterization of interesting enzymes can be performed to determine their substrate 
and product profiles.  
2.2 Results and discussion 
2.2.1 Design of the degenerate primers 
Detection of interested genes by PCR is a commonly used strategies in molecular 
biology (11). Degenerate primers are used for amplifying a family of unknown genes 
by incorporating deoxyinosines in the primer sequence to create the genetic diversity. 
Inosine is a natural nucleoside commonly present in transfer RNAs and is able to base 
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pair with thymidine, cytosine, and, to a less extent, adenine. This strategy has already 
been employed for discovery of Type III PKS, such as acridone synthase from 
Huperzia serrate (12), and octaketide synthase from Aloe arborescens (13).  
Fourteen different enzymes from plant Type III PKS family were chosen as the 
template for design of the degenerate primers. The phylogenetic relationship of these 
fourteen enzymes and their main polyketide products are shown in Figure 2.2. The 
mRNA sequences coding these enzymes were aligned using ClustalW. From the 
alignment, regions shared high homologies were found and six of them were chosen 
to create the degenerate primers. The locations of the three sets of conserved regions, 
F1, F2, F3, R1, R2 and R3, mapped on the M. sativa chalcone synthase 2 (CHS2) 
gene and protein sequence are shown in Figure 2.3. Three primer sets annealing at 
these regions (shown in yellow, green, and pink) amplify three gradually shorter 
fragments to perform a nest PCR, with fragment lengths of approximately 800bp 
(yellow, region F1 and R3), 770bp (green, region F2 and R2), and 400bp (pink, region 
F3 and R1). Nest PCR would help to eliminate the false positive and also enrich the 
genetic materials of interest. The core fragments that were ~ 400bp in length were 
specially designed in the region that contained the important residues, such as 
Thr-197 and Gly-256. Those residues play an important role in substrate recognition 
and elongation of a Type III PKS. In this case, alignment of the resultant core 
fragments would give insights into the potential classification of the Type III PKSs. 
This would help avoiding cloning and characterizing less desirable enzymes. 
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2.2.2 Validation of degenerate primers 
As the degenerate primers is the first key element to insure the success of 
amplification of the desired Type III PKS, Type III PKSs from Hypericum perforatum 
are used to validate the degenerate primers. Hypericum perforatum, known as St. 
John’s Worts, is a medical plant and its extracts are commonly used for the treatment 
of mild to moderate depression (14). Four polyketides, hyperforin, adhyperforin, 
hyperfricin, and pseudohypericin are found in this plant and believed to be bioactive 
(15). Thus, Hypericum perforatum is ideal to be used as the model system to test the 
degenerate primers as it is a medical plant and has a number of PKSs whose 
sequences are known. Four type III PKSs have been cloned from H. perforatum: 
chalcone synthase, benzophenone synthase, PKS1, a hyperforin synthase and PKS2, 
which synthesizes the octaketide precursor to hyperforin, emodin anthrone (16). The 
primary sequences of these four enzymes are divergent, so the ~400bp fragment may 
be enough to differentiate the four genes. The validation experiment design is shown 
in Figure 2.4. 
In this study, the genetic materials were collected from the improved strain 
Hypericum perforatum var. Topas. Seeds were germinated on Murashige-Skoog 
media and grow for four weeks. Total RNA was extracted from immature tissue, 
purified and concentrated, and then was used to create the cDNA library. One positive 
control gene, which synthesizes the RuBisCo (Ribulose-1,5-bisphosphate carboxylase 
oxygenase), was used to ensure the successful preparation of mRNA and cDNA 
library. RuBisco is the most abundant enzyme in green plants, so it was chosen as the 
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positive control. Specific primers based on the published mRNA sequence of the four 
known PKSs (BPS, CHS, PKS1 and PKS2) were used to amplify the corresponding 
genes from the cDNA library (Figure 2.4). The amplified fragments were cloned into 
pET 26 vectors and confirmed by sequencing. The identities were greater than 90% 
versus the templates (BPS. 797/855 nt, 93%; CHS, 1004/1067 nt, 94%; PKS1, 
960/981 nt, 97%; PKS2, 1057/1078 nt, 98%). Then, degenerate primers were used to 
amplify the Type III PKSs based on nest PCR protocol. Basically, PKS-F1/PKS-R3 
were used to amplify the ~800 bp fragment and then , the product was used as 
template for the second round of amplification using PKS-F2/PKS-R2, and the 
product of second round served as the template for the last round of amplification by 
PKS-F3/PKS-R1. Product from the third round of nest PCR can be visible on agarose 
gel as shown on Figure 2.5.   
The fragments were cloned into a vector and 26 colonies were sequenced. The 
results showed that out of the 26, some were belonging to CHS and BPS from H. 
perforatum, and an additional PKS was found. The sequence identity of various 
clones to CHS, BPS, PKS1 and PKS2 was shown in Table 2.1.  
A BLAST search based on the ~400 nt sequence of the unknown gene fragments 
(clones #5 and #8) indicates it has significant homology to plant CHS and maybe root 
specific. Our inability to identify PKS1 and PKS2 may due to the low expression 
level of these two genes, also may due to the availability of these two genes in the 
immature plant tissue.  
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Nonetheless, the validation data confirmed that the degenerate primers are able 
to amplify the Type III gene from a plant cDNA library. During the degenerate primer 
design process, no Type III PKS from H. perforatum was included, which proved that 
the degenerate primers designed were able to amplify Type III PKS from general 
plant tissue.  
2.2.3 Identification of target plants 
The target plants were selected based on two criteria: firstly, the plant needs to be 
bioactive, evidenced by use in traditional medicine and/or findings of high-valued 
compounds reported by scientific journals; secondly, the plant has been reported to 
produce phloroglucinol or derivative compounds. Searching scientific database, 
several target plants have been picked out over a wide range of species. Trees of 
Eucalyptus and ferns of Dryopteris are two groups of plants in which 
acylphloroglucinols are particularly abundant and no cloning of relevant genes. 
Eucalypts produce a wide variety of acylphloroglucinol compounds which may be 
formylated or acylphloroglucinol-terpene adducts (e.g. euglobals and macrocarpals) 
(17). For example, the compound grandinol, produced by Eucalyptus grandis, is the 
most-studied acylphloroglucinols. Gradinol serves as a growth regulator in the plants 
and can inhibit germination (8). Eucalypt polyketide natural products are also known 
to be antiviral, antibacterial, anticancer, and cariostatic (inhibit the growth of bacteria 
that cause tooth decay), and Eucalypts have been used by the Aboriginal people of 
Australia for the treatment of colds, influenza, toothache, snakebites, fevers, and other 
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ailments (17). The plant E. camaldulensis, from which the compound phloroglucinol 
has been isolated in the past, is an important species to study. 
2.2.4 Screening of PKS genes in target plants 
Based on the two criteria and literature study, two plants, Eucalyptus 
camadulensis var. Silverton Province and Eucalyptus robusta were chosen for study. 
E. robusta produces the dimeric and monomeric acylphloroglucinols Robustaol A and 
B, respectively, as well as the acylphloroglucinol-terpene adducts Robustadial A and 
B. The leaves of E. robusta are used to produce an anti-malarial medicine, “Da Ye 
An,” in China, and also to treat bacterial illnesses and dysentery. E. camaldulensis, or 
red gum, was chosen as the second target species. It is an abundant tree also known to 
produce acylphloroglucinol-terpene adducts. 
Specimens of the target plants E. camaldulensis var. Silverton Province and E. 
robusta were obtained for study. Briefly, the collected leaf tissue was flash-frozen in 
liquid nitrogen and crushed, and total RNA was extracted from the plant tissue and 
used to create cDNA libraries. This cDNA was used as the template for nested PCR. 
At each stage, PCR products were analyzed by agarose gel electrophoresis, and in the 
initial step, an amplification of a fragment of the abundant mRNA for RuBisCo 
(Ribulose-1,5-bisphosphate carboxylase oxygenase) was also used as a control. The 
first and second amplifications did not result in bands of the expected size, with the 
exception of the RuBisCo control, but the final amplification gave a fragment of the 
appropriate size (~400 nt). The fragments were then digested and ligated into a vector 
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for sequencing. The absence of product bands until the third nested PCR indicates the 
need for this strategy due to low abundance of the mRNAs of interest in Eucalyptus.  
A total of 94 clones and 27 clones were sequenced from the cDNA libraries 
created from the leaves of E. camaldulensis and E. robusta, respectively. Depending 
on the threshold (i.e. the number of different amino acids in the cloned DNA 
fragments), the number of different genes could range from 5 to 97. If the threshold in 
the validation experiment was used as a reference (i.e. genes with 80% sequence 
identity are considered the same), the identified DNA fragments could be classified 
into 11 groups, representing 11 unique putative Type III PKSs genes. To make it more 
stringent, these 11 groups can be further consolidated into 5 groups (PKS1-5) 
according to the characteristic residues. Representation of each group ranged from 1 
to approximately 50 clones and two of the three conserved catalytic triad residues in 
all known Type III PKSs (Cys and His) were present.  
Based on the translated sequence, specifically on the Gly-256 (M. sativa 
chalcone synthase numbering) equivalent and nearby residues, the activity of a new 
Type III PKS could be inferred. Enzymes utilizing coumaroyl-CoA as the priming 
acyl-CoA (chalcone synthase and stilbene synthase enzymes) typically possess a 
glycine at the equivalent of CHS Gly-256, and a DGH (Asp-255, Gly-256, His-257) 
pattern, indicating that PKS4 likely represents CHS or STS enzymes. Benzophenone 
synthases possess a TAH pattern, which is shared by PKS2. Two enzymes possessed 
unusual residues at those locations: AGH was seen in PKS1, and AAH for PKS5.  
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The translated sequence of PKS3 shows that it possesses the residues EGQ at the CHS 
Asp-255, Gly-256, His-257 equivalent positions. ClustalW alignment of 
representative translated sequences from each group is shown in Figure 2.6, and 
highlights the diversity present among these five putative Type III PKS enzymes.  
2.2.5 Cloning of full length PKS genes using RACE-PCR 
To further investigate the cloned putative Type III PKS fragments, RACE-PCR 
(rapid amplification of cDNA ends-polymerase chain reaction) was used to clone the 
full-length genes encoding the three Eucalyptus Type III PKSs. However, for Pks5, as 
the amount of this gene in the cDNA library was so low, the RACE-PCR failed to 
obtain the 3’- and 5’-end of this gene. Thus we decided to focus on Pks1 and Pks3. 
The 3’- and 5’-ends of these two genes were obtained from RACE-PCR, and specific 
primers were designed to obtain the full length gene. Full length genes were 
successfully amplified from the cDNA library (Figure 2.7). The resulting full-length 
gene for Pks 1, consists of 1170 nucleotides, which corresponds to 389 amino acid 
residues, and for Pks 3, consists of 1182 nucleotides, which corresponds to 408 amino 
acid residues. The two full length genes were sequenced. BLAST search indicates 
both Pks1 and Pks3 share 75% sequence identity with M. sativa chalcone synthase. 
Bioinformatic analysis indicates that the catalytic triad residues (Cys, His, Asn) of 
Type III PKSs are all present in this protein. By comparing all the conserved residues 
in CHSs, including the catalytic triad: Cys164, His303, Asn336; the active sites: 
Thr197, Ile254, Gly256, Ser338; the catalytic site: Met137, Gly211, Gly216, Pro375, 
and the gate keepers: Phe215, Phe265, it was found that all these residues are 
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conserved in Pks3, while Pks1 has Ile265 instead of Phe265. Therefore, we selected 
Pks3 for further characterization. 
2.2.6 Enzyme characterization and product identification 
In order to produce the large quantities of enzymes required for characterization 
studies, a heterologous host was needed for over-expression. Escherichia coli was 
chosen as the heterologous host. It is widely used for heterologous expression due to 
its fast growth, ease of transformation and mature and numerous availability of DNA 
cloning tools (18). The pks1 gene with C-terminal His6 was cloned into the 
IPTG-inducible pET26b(+) vector, which possesses a PT7 promoter, and expressed as 
a soluble protein in E. coli. A PKS1 protein band is clearly visible by SDS-PAGE 
analysis of purified soluble lysate from E. coli PKS1 expression. However, the purity 
was poor, so gel filtration was used to enhance the purity (Figure 2.8). 
At the same time, M. sativa chalcone synthase was cloned and purified to serve 
as the positive control. Enzymatic activity assay was carried out as described 
elsewhere (19). 14 different CoAs were tested as the starter unit whereas malonyl 
CoA was used as the extension unit. Several HPLC programs were tested as listed in 
Table 2.3 and 2.4, and the highlighted one was chosen for CoA separation and 
product discovery.  
As for M. sativa chalcone synthase, 4-coumaroyl CoA was used as the starter 
unit and malonyl CoA as the extension unit. 4-coumaroyl-NAC was chemically 
synthesized and used as the starter unit.  The chemical structure of 
4-coumaroyl-NAC was confirmed by both LC-MS and NMR (data not shown). Both 
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CHS and Pks1 were incubated with these two substrates and the expected product 
peak for naringenin was detected (Figure 2.9), which indicated that the enzymes were 
active. However, after testing all possible starter CoAs, no novel product was 
identified, which indicates that Pks1 is a member of the CHS family of Type III PKSs 
and shares the same function as M. sativa chalcone synthase. 
2.3 Conclusion 
In this study we developed a PCR-based screening method able to identify novel 
Type III PKSs in medicinal plants. The screening system was successfully validated 
by identifying two known Type III PKSs and one unknown Type III PKS from 
Hypericum perforatum.  Initial results from screening Eucalyptus species have been 
promising, and led to the identification of gene fragments from at least five putative 
Type III PKS enzymes between E. robusta and E. camaldulensis, including two 
enzymes which appear to be conserved in both species. Bioinformatic studies allowed 
us to identify one putative benzophenone synthase and three putative chalcone or 
stilbene synthases. RACE-PCR was used to obtain the full-length genes encoding two 
Eucalyptus Type III PKSs, however, further biochemical characterization showed that 
Pks1 Type III PKS belongs to the CHS family and has a same function as M. sativa 
chalcone synthase.  
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2.4 Materials and methods  
2.4.1  Strains and reagents 
E. coli DH5α was obtained from the University of Illinois at Urbana-Champaign 
Biochemistry Department's Media Preparation Facility (Urbana, IL). Hypericum 
perforatum var. Topas seeds were purchased from Sand Mountain Herbs (Fyffe, AL). 
Eucalyptus robusta and Eucalyptus camaldulensis var. Silverton Province plants were 
obtained from Windmill Outback Nursery (Louisa, VA). Plasmid pET26b(+) and 
pET28a(+) were obtained from Novagen (Madison, WI). All restriction 
endonucleases, as well as T4 DNA ligase and antarctic phosphatase, were purchased 
from New England Biolabs (Beverly, MA). The QIAprep Spin Plasmid Mini-prep Kit, 
QIAquick PCR Purification Kit, QIAquick Gel Extraction Kit, and RNeasy MinElute 
Cleanup Kit were purchased from Qiagen (Valencia, CA). The Total RNA Isolation 
Mini Kit was obtained from Agilent Technologies (Santa Clara, CA). All primers 
were synthesized by Integrated DNA Technologies (Coralville, IA). 5 PRIME 
MasterMix was purchased from 5 PRIME Inc. (Gaithersburg, MD). Unless otherwise 
noted, all other reagents were purchased from Sigma-Aldrich (St. Louis, MO). 
2.4.2 Degenerate primer design 
The mRNA sequences of fourteen enzymes in the plant Type III PKS family were 
used as the templates to design degenerate primers: Hypericum androsoemum 
benzophenone synthase (BPS), Hordeum vulgare homoeriodictyol/eriodictyol 
synthase (HEDS), Medicago sativa chalcone synthase 2 (CHS2), Arachis hypogea 
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stilbene synthase (STS), Pinus sylvestris stilbene synthase (STS), Gerbera hybrida 
2-pyrone synthase (2-PS), Aloe arborescens octaketide synthase (OKS), Aloe 
arborescens pentaketide chromone synthase (PCS), Rheum palmatum aloesone 
synthase (ALS), Rheum palmatum benzalacetone synthase (BAS), Humulus lupulus 
isovalerophenone synthase (VPS), Hydrangea macrophylla stilbenecarboxylate 
synthase 1 (STCS1), Hydrangea macrophylla coumaroyl triacetic acid lactone 
synthase (CTAS), and Huperzia serrata acridone synthase (ACS).  
The mRNA sequences of the fourteen above enzymes were aligned using the 
ClustalW tool in the Biology Workbench suite (http://workbench.sdsc.edu) (20). 
Highly similar regions were identified from the alignment, and the six regions chosen 
to create degenerate primers are mapped onto the M. sativa CHS2 mRNA and protein 
sequences in Figure 2.3. The conserved regions were denoted F1, F2, F3, R1, R2, and 
R3, and used to design primers of the same name. To keep degeneracy as low as 
possible, less conserved bases were replaced with deoxyinosine, with a maximum of 
three deoxyinosine nucleotides per primer. The primer sequences, their levels of 
degeneracy, and definitions of mixed bases are given in Table 2.5. Three sets of 
primers are designed to perform nest PCR, which is essential as repeating of F1-R3 
cannot amplify desired fragments and using F3-R1 initially cannot generate enough 
amount of the desired fragment either. Restriction sites were added to primers 
PKS-F3 (NheI) and PKS-R1 (XhoI) to facilitate cloning the smallest fragments into a 
vector for sequencing; those primers are PKS-F3-F and PKS-R1-F. Primers both with 
and without flanking bases were generated because it was unclear whether 
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non-hybridizing, flanking nucleotides would inhibit the amplification reaction. Based 
on the M. sativa CHS2 mRNA (Figure 2.3), the fragment amplified by PKS-F1 and 
PKS-R3 is 803 nt in length; the fragment amplified by PKS-F2 and PKS-R2 is 776 nt; 
and the fragment amplified by PKS-F3(-F) and PKS-R1(-F) is 407 nt. 
2.4.3 Seed sterilization and germination 
Before germinating, H. perforatum var. Topas seeds were sterilized by a four-step 
process: (1) seeds were washed in a solution of 70% ethanol and 0.1% Tween-20 with 
vigorous mixing for 1 minute; (2) seeds were washed in a solution of 5% NaOCl 
(bleach) with vigorous mixing for 10 minutes; (3) seeds were then rinsed with three 
washes of distilled, deionized water which was sterilized through a 0.22 µm syringe 
filter; (4) seeds were soaked in a solution of Agribrom antifungal dissolved in sterile 
distilled, deionized water and incubated in the dark at 4 °C for 48 hours. Subsequently 
the sterilized seeds were rinsed in sterile distilled, deionized water, plated on 
Murashige-Skoog (no sucrose) plates (Murashige-Skoog basal salts, MES, 0.7% agar, 
pH 5.7) sealed with gas-permeable tape (3M, St. Paul, MN) and incubated in a lighted 
room to induce germination. After approximately four weeks, seedlings were removed 
from agar plates and plant tissue was collected and cDNA prepared as described 
below.  
2.4.4 Collection of plant tissue 
Plant tissue (leaf) was cut from live plants and immediately frozen on liquid 
nitrogen to prevent degradation of RNA. Frozen tissue was crushed to fine powder 
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using a mortar and pestle cooled to freezing using liquid nitrogen. Crushed plant 
tissue was stored at -80 °C until RNA extraction. 
2.4.5 Total RNA isolation and concentration and cDNA synthesis 
Total RNA was purified from crushed plant tissue using the Agilent Total RNA 
Isolation Mini Kit according to the manufacturer’s instructions. Approximately 100 
mg of plant tissue was used in each RNA purification. To purify and concentrate 
RNA, the Qiagen RNeasy MinElute Cleanup Kit was used according to the 
manufacturer’s instructions. Total RNA was visualized by agarose gel electrophoresis 
and concentration and purity were determined using a NanoDrop (Thermo Fisher 
Scientific, Waltham, MA). Purified, concentrated total RNA was used as the template 
for cDNA synthesis using Transcriptor II reverse transcriptase enzyme (Invitrogen, 
Carlsbad, CA) and anchored Oligo-dT20 primer (Invitrogen, Carlsbad, CA) according 
to the manufacturer’s instructions. 
2.4.6 Screen validation using Hypericum perforatum var. Topas 
To verify their expression, full-length genes for H. perforatum CHS, BPS, PKS1, 
and PKS2 were amplified from H. perforatum cDNA using the specific primers 
shown in Table 2.6 and 5 PRIME MasterMix according to the manufacturer’s 
instructions (PCR program: 95 °C, 3 min; [94 °C, 1 min; 50 °C 1 min; 68 °C 1 min 30 
sec] x 50; 68 °C, 7 min). PCR products were analyzed by agarose gel electrophoresis 
and then bands of the appropriate size were purified by gel purification and extraction. 
DNA sequencing reactions were performed using the same primers initially used to 
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amplify the genes (Table 2.6) and the BigDye Terminator v3.1 Cycle Sequencing Kit 
(Applied Biosystems, Foster City, CA) according to the manufacturer’s instructions. 
DNA was sequenced by the Biotechnology Core DNA Sequencing Laboratory at the 
University of Illinois at Urbana-Champaign (Urbana, IL). Comparing the sequencing 
results versus published sequences confirmed that all four PKSs were expressed in the 
H. perforatum seedlings. 
Amplifications with the degenerate primers were performed using the following 
PCR program: 95 °C, 3 min; [94 °C, 1 min; 50 °C 1 min; 68 °C 1 min 30 sec] x 50; 
68 °C, 7 min. DNA fragments were amplified from cDNA using the primers shown in 
Table 2.5 and 5 PRIME MasterMix according to the manufacturer’s instructions. 
Amplification of the RuBisCo fragment was performed using specific primers for the 
RuBisCo gene in conjunction with the first amplification using PKS-F1 and PKS-R3 
primers, to verify the amplification was successful and cDNA was present. For 
amplifications using cDNA as the template, 1 µl of cDNA was used; alternatively, 5 
µl of PCR product was used as the template for subsequent nested PCR amplifications 
using primers PKS-F2 and PKS-R2 or PKS-F3-F and PKS-R1-F.  
PCR-amplified ~400 nt DNA fragments were cloned into the pET26b(+) vector 
to facilitate DNA sequencing. The ~400 nt fragment was digested with NheI and XhoI 
(10 units enzyme per µg DNA), and the vector was digested with XbaI and XhoI (10 
units enzyme per µg DNA). Note that NheI and XbaI have compatible cohesive ends. 
After ligation using T4 DNA ligase the plasmid was transformed into E. coli DH5α 
and single colonies were picked. Presence of an insert of the correct size was verified 
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by colony PCR. Briefly, cells were collected from 200 µl overnight culture and 
resuspended in 200 µl sterile distilled, deionized water. The samples were boiled for 
ten minutes, cooled to room temperature, and then spun at max speed in a bench top 
microcentrifuge for three minutes to pellet cell debris. A PCR amplification using Taq 
DNA polymerase (Invitrogen, Carlsbad, CA) was set up according to the 
manufacturer’s instructions with 5 µl of the soluble cell lysate as template and using 
primers specific to the T7 promoter and the T7 terminator. The PCR product was 
analyzed by agarose gel electrophoresis. A plasmid with resulting PCR product of 
size ~500 nt was purified and submitted for DNA sequencing. Sequencing reactions 
were performed using primers specific to the T7 terminator and the BigDye 
Terminator v3.1 Cycle Sequencing Kit. DNA was sequenced by the Biotechnology 
Core DNA Sequencing Laboratory at the University of Illinois at Urbana-Champaign 
(Urbana, IL). 
DNA sequencing of 26 fragments in pET26b(+) identified the ~400 bp 
fragments as belonging to the genes for H. perforatum CHS, H. perforatum BPS, and 
an additional, previously unknown gene, based on sequence homology (Table 2.1). 
The other two enzymes, PKS1 and PKS2, were not identified, probably due to lower 
relative expression (and thus abundance of mRNA) in the young plants. 
2.4.7 Screening Eucalyptus species 
Leaf tissue was taken from E. robusta and E. camaldulensis var. Silverton 
Province trees (~1.5 m height) for RNA isolation. Collection of plant tissue, RNA 
isolation, and cDNA synthesis were completed as described in the sections above. 
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Degenerate primer nested PCR, cloning of ~400 nt fragments, and DNA sequencing 
were performed as described above for H. perforatum. A total of 27 individual clones 
were submitted for sequencing from E. robusta and 94 from E. camaldulensis. 
ClustalW and BLAST analysis using the Biology Workbench Suite (20) were used to 
analyze the resulting DNA and translated protein sequences. Depending on the cut-off 
(i.e. the number of different amino acids in the cloned DNA fragments), the number 
of different Type III PKS genes ranges from 5 to 97 (Table 2.2). Phylogenetic 
analysis of all the Type III PKS fragments is given in Figure 2.10. 
2.4.8 RACE PCR 
The core fragment of EC2 was subjected to RACE PCR using gene specific 
primers (Figure 2.7) and the protocol of 3’/5’ RACE system for Rapid Amplification 
of cDNA Ends Kits Version 2.0 (Invitrogen, Carlsbad, CA). The PCR program 
consists of 94 °C (2 min), 35 cycles at 94 °C (1 min), 55 °C (30s) and 72 °C (2 min), 
and a final 10 min extension at 72 °C. A plasmid with resulting PCR product of size 
~1000 nt was purified and submitted for DNA sequencing. Sequencing reactions were 
performed using primers specific to the T7 terminator and the BigDye® Terminator 
v3.1 Cycle Sequencing Kit. 
2.4.9 Protein purification 
Plasmids pET26b(+)-EC2, pET26(+)-ER4 and pET26(+)-CHS were transformed 
into E.coli BL21 (DE3) and single colonies were picked and inoculated 5 mL LB 
containing 50 μg kanamycin mL-1 . Following overnight growth at 37 °C, and this 
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culture was used to inoculate 500 mL TB containing the appropriate antibiotic, and 
grown at 37 °C until the optical density at 600 nm reached 0.8. Protein expression was 
induced with the addition of 0.25mM isopropyl-β-D-thiogalactopyranoside (IPTG), 
and growth was continued for an additional 18 hours at 20 °C. The flasks were chilled 
for 30 minutes, and then the cells were harvested by centrifugation (6000 g, 4 °C, 10 
minutes). The resulting pellet was resuspended in 2 mL lysis buffer (10 mM 
imidazole, 50 mM sodium phosphate buffer, 300 mM NaCl, 10 mM imidazole, 15% 
glycerol, pH 8.0, 1 mg/mL lysozyme) per gram cell weight and frozen at -80 °C. 
Subsequently, cells were lysed using sonication and cellular debris was removed by 
centrifugation (40,000 g, 4 °C, 10 minutes). Recombinant proteins were purified by 
chromatography on Ni-NTA resin by amino-terminal hexahistidine affinity tag. 
Captured proteins was washed with wash buffer (20 and 50 mM imidazole, 50 mM 
sodium phosphate buffer, 300 mM NaCl, 20 or 50 mM imidazole, 15% glycerol, pH 
8.0) and finally eluted in elution buffer (200 mM imidazole, 50 mM sodium 
phosphate buffer, 300 mM NaCl, 200 mM imidazole, 15% glycerol, pH 8.0). The 
protein content of individual elution fractions was estimated using Quick Start 
Bradford Protein Assay (Bio-Rad, Hercules, CA) and the appropriate fractions were 
pooled and buffer exchanged into 10 mM phosphate buffer pH 7.5 containing 15% 
glycerol at 4°C. The protein was concentrated using an Amicon Ultra centrifugal filter 
device (Millipore, Billerca, MA). Representative SDS-PAGE analysis of recombinant 
protein was shown in Figure 2.8.  
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2.4.10 Polyacrylamide Gel Electrophoresis (SDS-PAGE) 
Protein standards, Powerpac 300 power supply, Mini-PROTEAN 3 assembly, and 
precast acrylamide gels were purchased from Bio-Rad (Hercules, CA). Varying 
amounts of sample, dependent upon protein concentration, were mixed with 2 μl 
SDS-PAGE loading buffer (30% glycerol, 1% SDS, 0.3% bromophenol blue, 0.5 M 
Tris-HCl, pH 6.8) and water to a final volume of 20 μl, Samples were denatured at 
98°C for 10 minutes, cooled to 4°C, and then loaded onto a gel in a Bio-Rad 
Mini-PROTEAN 3 assembly. Voltage was supplied by a Powerpac 300 supply at a 
voltage of 100 V for 100 minutes. Gels were stained with SimplyBlueTM Safestain 
from Invitrogen (Carlsbad, CA) followed by destaining overnight in distilled water. 
Destained SDS-PAGE gels were scanned subsequently discarded. 
2.4.11 Determination of activity 
Experiments were conducted according to the method of Mckhann, et al. (19) 
with some modifications. The experiments were carried out in triplicates using a 
range of different starting CoAs. For each reaction, substrate was incubated with EC2 
enzyme (0.5 mg/ml) in PBS buffer (pH 7.5) at 37°C for 15 minutes. Usually， 0.5 μM 
enzyme is used and 100 μM malonyl CoA in a total reaction volume of 400 μl. The 
concentration of priming acyl-CoA was 10 μl. The reaction mixture was incubated at 
37°C for 5 minutes before addition of malonyl-CoA. The reaction was quenched by 
the addition of 20 μl 20% HCl and kept room temperature until HPLC analysis. The 
reactions were analyzed using an Agilent 1100 Series HPLC and ZORBAX SB-C18 
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reverse-phase column (3.0 x 150 mm, 3.5 μm) (Aglient Technologies, Palo Alto, CA) 
monitoring at 254 nm.  
2.4.12 Product HPLC analysis method 
Product analysis method was conducted by comparing a series of different HPLC 
programs. An Agilent 1100 Series HPLC and ZORBAX SB-C18 reverse-phase 
column (3.0 x 150 mm, 3.5 μm) (Aglient Technologies, Palo Alto, CA) was used to 
monitor at 280 nm and at a flow rate of 0.5 mL/min at 25°C. Solvent A is water with 
1% acetic acid and solvent B is methanol.  
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Figure 2.1 Examples of natural products derived from plants. 
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Figure 2.2 Phylogenetic analysis of the fourteen Type III PKS enzymes used to create 
degenerate primers in this study. The primary products of the enzymes are shown. The 
enzymes are, in order: HEDS, homoeriodictyol/eriodictyol synthase; ALS, aloesone synthase; 
BPS, benzophenone synthase; OKS, octaketide synthase; PCS, pentaketide chromone 
synthaes; STS, stilbene synthase; ACS, acridone synthase; CTAS, coumaroyl triacetic acid 
synthase; STCS1, stilbenecarboxylate synthase 1; 2-PS, 2-pyrone synthase; VPS, 
isovalerophenone synthase; CHS2, chalcone synthase 2; BAS, benzalacetone synthase. 
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Figure 2.3 Locations of the three sets of conserved regions used to create degenerate primers, 
mapped onto the M. sativa CHS2 gene and protein, are shown in yellow, green, and pink, 
corresponding to F1, F2, F3, R1, R2, and R3, respectively. Active site residues Cys-152, 
His-305, and Asn-338 are shown in red and marked with asterisks. Residues which are known 
to affect substrate preference and elongation number, Thr-197, Gly-256, and Ser-338, are 
shown in blue and marked with a triangle. 
      M  V  S  V  S  E  I  R  K  A  Q  R  A  E  G  P  A  T  I  L   
1     atggtgagtgtgtctgaaattcgtaaagctcaaagggcagaaggccctgcaactatcttg  60 
 
      A  I  G  T  A  N  P  A  N  C  V  E  Q  S  T  Y  P  D  F  Y   
61    gccattggcactgcaaatccagcaaattgtgttgaacaaagcacttatcctgatttttac  120 
 
      F  K  I  T  N  S  E  H  K  T  E  L  K  E  K  F  Q  R  M  C   
121   tttaaaattacaaatagtgagcacaaaactgaacttaaagagaaatttcagcgcatgtgt  180 
 
      D  K  S  M  I  K  R  R  Y  M  Y  L  T  E  E  I  L  K  E  N   
181   gataaatctatgatcaagaggagatacatgtatctaacagaggagattttgaaagaaaat  240 
 
      P  N  V  C  E  Y  M  A  P  S  L  D  A  R  Q  D  M  V  V  V   
241   ccaaatgtttgtgaatacatggcaccttcattggatgcaaggcaagacatggtggtggta  300 
 
      E  V  P  R  L  G  K  E  A  A  V  K  A  I  K  E  W  G  Q  P   
301   gaggtacctagactagggaaggaggctgcagtgaaggctataaaagaatggggtcaacca  360 
 
      K  S  K  I  T  H  L  I  V  C  T  T  S  G  V  D  M  P  G  A   
361   aagtcaaagattactcacttaatcgtttgcaccacaagtggtgtcgacatgcctggagcc  420 
 
      D  Y  Q  L  T  K  L  L  G  L  R  P  Y  V  K  R  Y  M  M  Y   
421   gattatcaactcaccaaactcttaggtcttcgcccatatgtgaaaaggtacatgatgtac  480 
               * 
      Q  Q  G  C  F  A  G  G  T  V  L  R  L  A  K  D  L  A  E  N   
481   caacaagggtgttttgcaggtggcacggtgcttcgtttggctaaagatttggctgagaac  540 
                                                      ▼ 
      N  K  G  A  R  V  L  V  V  C  S  E  V  T  A  V  T  F  R  G   
541   aacaaaggtgctcgtgtgttggttgtttgttctgaggtcaccgctgtcacatttcgtggg  600 
 
      P  S  D  T  H  L  D  S  L  V  G  Q  A  L  F  G  D  G  A  A   
601   cctagtgatactcacttggacagccttgttggacaagcactatttggagatggagctgct  660 
 
      A  L  I  V  G  S  D  P  V  P  E  I  E  K  P  I  F  E  M  V   
661   gcactcattgttggttctgatccagtaccagaaattgagaaacctatatttgagatggtt  720 
                                                   ▼ 
      W  T  A  Q  T  I  A  P  D  S  E  G  A  I  D  G  H  L  R  E   
721   tggactgcacaaacaattgctcctgatagtgaaggagccattgatggtcaccttcgtgaa  780 
 
      A  G  L  T  F  H  L  L  K  D  V  P  G  I  V  S  K  N  I  T   
781   gctggactaacatttcaccttcttaaagatgttcctgggattgtttcaaagaacatcact  840 
 
      K  A  L  V  E  A  F  E  P  L  G  I  S  D  Y  N  S  I  F  W   
841   aaagcattggttgaggctttcgagccattgggaatttctgattacaactcaatcttttgg  900 
            * 
      I  A  H  P  G  G  P  A  I  L  D  Q  V  E  Q  K  L  A  L  K   
901   attgcacatcctggtggacctgcaattctagatcaagtagagcaaaagttagccttaaag  960 
                                                   *     ▼ 
      P  E  K  M  N  A  T  R  E  V  L  S  E  Y  G  N  M  S  S  A   
961   cctgaaaagatgaatgcaactagagaagtgctaagtgaatatggaaatatgtcaagtgca  1020 
 
      C  V  L  F  I  L  D  E  M  R  K  K  S  T  Q  N  G  L  K  T   
1021  tgtgttttgtttatcttagatgaaatgagaaagaagtcaactcaaaacggattgaagaca  1080 
 
      T  G  E  G  L  E  W  G  V  L  F  G  F  G  P  G  L  T  I  E   
1081  acgggagaaggacttgaatggggtgtattgtttggttttggaccaggacttaccattgaa  1140 
 
      T  V  V  L  R  S  V  A  I  * 
1141  acagttgttttgcgtagcgtggctatatga  1170 
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Figure 2.4 Overview of the PCR-based method for discovering new Type III PKS genes. 
 
A:     L   Rub CHS  PKS1 PKS2 BPS  B:  L    D 
   
Figure 2.5 (A) Gene fragments (~1000 nt) for H. perforatum RuBisCo (Rub), CHS, PKS1, 
PKS2 and Benzophenone synthase(BPS), amplified by specific primers and analyzed by 
agarose gel electrophoresis. (B) The nest PCR product from the third round of PCR (~400 nt) 
from H. perforatum. 
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Figure 2.6 Alignment of Type III PKS fragments from five distinct enzymes discovered in 
this work. Catalytic histidine residue is marked in red. The CHS Thr-197 and CHS Gly-256 
equivalent residues are marked in blue.  
 
 
Figure 2.7 Amplification of the full length gene. The first two lanes used Taq for PCR, and 
the first one had the stop codon while the second one contained the His-tag. The third and 
fourth lane used phusion for PCR and same order as the first two. 
 
           L  Pks3  Pks3 after gel filtration 
 
Figure 2.8 Pks3 protein before and after gel filtration 
 PKS1    AKDVAENNKGARVLVVCAEITVCTFRGPTETYLDNLVGQALFGDGASSVIVGSDPVPGV-ERPLYEIVS
PKS2    AKDVAENNANARVLVVCAENTAMTFHAPNESHLDVIVGQAMFSDGAAALIIGANPDTAAGERAVFNILS
PKS3    AKDVAENNAGARVLVVCSEITVTTFRGPSAENLANLVGQAIFGDGAAALIIGSDPEIPA-ERPIFQLVW
PKS4    -KDVAENNKGARVLVVCSEITAVTFRGPSDTHLDSLVGQALFGDGAAALIVGSDPIPEI-ERPLFEMVW
PKS5    ----AENNKGARVLVVCSEITAVTFRGPSDTRLDNLVGQALFGDGAAALIVGSDPIPEI-EKPSFEMVW
 
PKS1    TSQTLLP-NSEGAIAGHVREIGLTIHLLKDVPGLISKNVEKNMTEAFHPLGITDWNSLFFIVHPGGTGI
PKS2    ASQTIVP-GSDGAITAHFYGMGMSYFLKEDVIPLFRDNIADVMKEAFSPLDVSDWNSLFYSIHPGGPAI
PKS3    TAETVLP-NSEGAIEGQLRDVGLTFGLSDGVPHLIANHIEKRLKEAFDSLGISDWNSIFWVPHPGGPAI
PKS4    TAQTILP-DSEGAIDGHLREVGLTFHLLKDVPGLISKNIEKALVEAFQPLGISDYNSIFWIAHPGGTAI
PKS5    TAQTIFPHDGEDIIAAHFREIGLTIHLHRDIPRLVSKNIEKAMIEAFQPLGISDYNSIFWIAHPGGRGI
50kD 
30kD 
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Figure 2.9 Detection of naringenin. The peak appeared at 29.786 min showed the production 
of naringenin. 
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Figure 2.10 Phylogenetic analysis of all the cloned Type III PKS fragments. 
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Table 2.1 Sequence identity (%) of ~400 nt fragments to known H. perforatum PKSs. 
# BPS CHS PKS1 PKS2 # BPS CHS PKS1 PKS2 
1 94 50 41 38 14 95 48 37 38 
2 93 50 43 34 15 54 87 45 43 
3 95 52 42 39 16 54 88 46 44 
4 55 88 47 43 17 55 87 45 43 
5* 55 54 35 30 18 58 80 46 46 
6 53 84 44 41 19 70 48 34 43 
7 55 81 46 45 20 53 84 45 42 
8* 58 49 36 43 21 54 88 46 44 
9 54 88 45 44 22 93 52 42 40 
10 90 49 35 40 23 94 48 36 38 
11 94 51 40 42 24 93 48 32 33 
12** - - - - 25 93 49 38 40 
13 90 47 32 37 26** 69 45 37 41 
*Previously uncharacterized Type III PKS 
**Low quality sequencing data. 
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Table 2.2 The number of expected different Type III PKS genes. 
Number of different amino 
acids (out of ~136) 
Number of expected 
different genes 
1 97 
5 31 
10 16 
15 12 
20 11 
30 9 
50 5 
 
Table 2.3 HPLC programs tested for CoA separation. 
 
 
Table 2.4 HPLC programs for product discovery. 
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Table 2.5 DNA sequence and degeneracy of primers used in this study. 
Primer Sequence, 5’  3’ Degeneracy
PKS-F1 GCIATIVMDSARTGGGGNC 288 
PKS-F2 TCIVRRATIACICAYBTNRT 576 
PKS-F3 GYIAARGAYITNGGNGARAACAA 256 
PKS-F3-F* GCGTTCGCTAGCGYIAARGAYITNGGNGARAACA 256 
PKS-R1 ATNSCISKICCICCRGGRTG 128 
PKS-R1-F* GCGTTCCTCGAGATNSCISKICCICCRGGRTG 128 
PKS-R2 CCSMWITCIWDNCCITCNCC 768 
PKS-R3 TCIAYNGTNADICCIGGNCC 384 
±Mixed bases B: C, G, T; D: A, G, T; H: A, C, T; K: G, T; M: A, C; N: A, C, G, T; 
 S: C, G; V: A, C, G; W: A, T ; Y: C, T.
*Additional flanking bases are in italics; the NheI restriction site is underlined. 
**Additional flanking bases are in italics; the XhoI restriction site is underlined. 
 
Table 2.6 Gene-specific primers for H. perforatum Type III PKSs. 
Primer Sequence, 5’  3’ 
CHS-F ATGGTGACCGTGGAAGAAGTCAG
CHS-R TTAATATGCGACACTGTGAAGGACCAC
BPS-F ATGGCCCCGGCGATG
BPS-R CTGGAGAATTGGGACACTCTGGAG
PKS1-F ATGTCTAACTTGGAGACCAATGGCTC
PKS1-R TCATAGGCATAGGCTTCGAAGAAGG
PKS2-F ATGGGTTCCCTTGACAATGGTTC
PKS2-R TTAGAGAGGCACACTTCGGAGC
 
Table 2.7 Gene-specific primers for RACE PCR. 
Primer Sequence, 5’  3’ 
EC2-F1 CGACACCGAGACCTACCTGGACAACC
EC2-F2 CGAGTGGGCCAGGCTCTGTTCG
EC2-F3 CGATTCGCTAGCGATGGCGCCTCCTCCACC
EC2-R1 TTCGCTAGCTGTCCAGGTAGGTCTCG
EC2-R2 ACAGAGCCTGGCCCAC
EC2-R3 GGTGGAGGAGGCGCCATC
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Chapter 3 Deciphering a Cryptic Biosynthetic Pathway from 
Streptomyces griseus by a Synthetic Biology Approach 
3.1 Introduction 
Over the past 10 years, there has been a resurgence of interest in the investigation 
of natural products as a source of new drugs.  Around 78% of antibacterial or 
anticancer drugs are natural products or have been derived from natural products (1).  
Although many effective drugs have been discovered, the need for new therapeutic 
agents remains due to the increasing antibiotic resistance to existing drugs and the 
recent threat of bioterrorism.  In the meantime, computational analysis of sequenced 
genomes and metagenomes has revealed numerous gene clusters that are potentially 
involved in the biosynthesis of natural products. Over the last decade, the genome 
sequences of over 1900 organisms have been released; with many more soon to be 
completed (http://www.genomesonline.org/cgi-bin/GOLD/bin/gold.cgi). There is no 
doubt that a great deal of valuable information hidden within these sequence data that 
are related to production of high-valued compounds, biosynthesis of promising drugs, 
and elucidation of mechanisms of various diseases.  
However, only a small fraction of this rich genome sequencing data has been 
exploited. Our understanding of the specific roles of genes and the functions of those 
pathways in the whole cell is still limited. For example, actinomycetes are 
well-known of producing bioactive natural products, many of which have exhibited 
important medical properties (2).  Recently revealed genome sequencing data clearly 
showed that the number of pathways coding for putative valuable natural products 
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largely outnumbers the number of currently known secondary metabolites for a given 
organism (3-6).  A total of 18 additional gene clusters involved in secondary 
metabolite production were discovered from the complete genome sequence of 
Streptomyces coelicolor, while the strain was previously known to produce only four 
compounds before the S. coelicolor genome project (7).  In addition, even a larger 
number of such pathways were present in the genome mining results of myxobacteria 
(8,9) and filamentous fungi (10-12).  These gene clusters, for which the 
corresponding natural metabolite is unknown, are named as “cryptic pathways” or 
“orphan pathways” (3,4).  Among the cryptic pathways, non-ribosomal peptide 
synthetases (NRPS) and polyketide synthases (PKS) occurred frequently, which were 
found in the biosynthesis of numerous bioactive natural products (13,14). 
Investigation into the unknown compounds synthesized by these two classes of 
enzymes may lead to the discovery of novel chemotherapeutic agents. However, since 
the widely used DNA cloning methods for studying biosynthetic pathways are 
time-consuming and labor-intensive, our motivation is to develop an efficient 
approach to decipher the cryptic natural product biosynthetic pathways. 
Up to date, two major approaches have been applied to biochemistry pathway 
characterization and analysis. The first group mainly focuses on activating native host 
genes while the second one takes the advantages of heterologous host gene expression 
(15). The first group of methods including screening of different culture conditions, 
which somehow helps to activate the cryptic pathway by introducing activators, 
environmental factors or remove repressors (4). However, this approach is usually 
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time-consuming and labor-intensive. Another main drawback is that even if a pathway 
is turned on, sometimes, it is still unclear which factor triggers the activation. Also, 
most of native producers grow slowly and are not commonly cultivable in the 
laboratory. It has been reported that only 1% of bacteria and 5% of fungi have been 
cultivated in the laboratory (16-18). On the other hand, the second group of 
heterologous host-based method can avoid these drawbacks since a well-characterized 
organism grows fast in the laboratory and has all the genetic tools available for 
engineering. This offers the possibility for metabolic engineering, which could 
enhance the production of target compounds and combinatorial biosynthesis which 
may generate new derivatives of a target compound. Most important of all, when 
using a well-characterized heterologous host which has a clear background profile, it 
would be much easier for product identification. There are many examples of 
heterologous expression of natural products, such as polyketides (19,20), 
methylenomycin furans (21), and phosphonic acids (22,23). However, there are 
limitations for this method as well. It is diﬃcult to transfer large biosynthetic 
pathways and it is also not easy to introduce single/multiple mutations or perform 
gene deletions. Other problems exist as well, such as low efficiency of promoter 
recognition, poor gene expression, or low yield (4). Therefore, the need for novel 
methods which are suitable for eﬃcient transfer, expression and modification of target 
biosynthetic pathways are obvious. 
Synthetic biology has emerged as a versatile tool for manipulating genes, 
pathways, networks, and whole cells (24). The fundamental idea behind synthetic 
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biology is that any biological system can be regarded as a combination of individual 
functional elements, a limited number of which can be recombined in novel 
configurations to modify existing properties or to create new ones (25).  As a broad 
field, the successful applications of synthetic biology such as synthesis of proteins 
that do not exist in nature, design and engineering of signaling and metabolic 
pathways, and rebuilding of new organisms make it an invaluable tool for natural 
product discovery.  
Recently, our laboratory developed a highly efficient method, “DNA assembler” 
to rapidly assemble a multiple-gene biochemical pathway in a single-step fashion by 
use of the in vivo homologous recombination mechanism in Saccharomyces 
cerevisiae (26). Because it is easy and efficient to perform homologous recombination 
in S. cerevisaie, S. cerevisiae was chosen as a host for DNA assembly (27-32). In this 
chapter, we attempted to further exploit the DNA assembler method to decipher 
cryptic pathways via synthetic biology for natural product discovery. Using one 
cryptic gene cluster in Streptomyces griseus as a test case (33), we demonstrated that 
a shuttle system can be very useful for rapid cloning of a gene cluster and its 
heterologous expression in a desired organism. This would solve the problem of 
introducing large gene clusters into a heterologous host. On the other hand, as it is 
easy to perform genetic manipulations by using this method, we can add different 
strong constitutive promoters in front of each gene in the gene cluster to control the 
gene expression. This would eliminate the problem of promoter recognitions and gene 
expression compared to heterologous expression alone. Future work will be focused 
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on product characterization, study of biosynthetic mechanisms by performing targeted 
gene deletions. 
3.2 Results and discussion 
3.2.1 Selection of a target gene cluster 
As we have mentioned above, the recent increasing availability of whole genome 
sequences have revised our view of the metabolic capabilities of microorganisms. A 
few orphan biosynthesis pathways have been identified by bio-informatics study 
(4,6,14). The discovery of these numerous pathways represents a treasure trove, 
which is likely to grow exponentially in the future, which will lead to the uncovering 
of many novel and possibly bio-active compounds. The few natural products that have 
been correlated with their orphan pathway are merely the tip of the iceberg, whilst 
plenty of metabolites await discovery (4). 
The complete genome sequence of Streptomyces griseus IFO 13350 was 
determined in 2008 (33).  Streptomyces griseus is a soil bacterium producing an 
antituberculosis agent, streptomycin, which was discovered more than 60 years ago 
and was the first aminoglycoside antibiotic. There are 8,545,929 base pairs (bp) in the 
linear chromosome and the average G+C content is 72.2%. It was predicted that there 
are 7,138 open reading frames, six rRNA operons (16S-23S-5S), and 66 tRNA genes. 
It contains extremely long terminal inverted repeats (TIRs) of 132,910 bp each. After 
comparisons with the genomes of two related species, Streptomyces coelicolor A3(2) 
and Streptomyces avermitilis, not only the characteristics of the S. griseus genome but 
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also the existence of 24 Streptomyces-specific proteins was clarified. 34 gene clusters 
or genes for the biosynthesis of known or unknown secondary metabolites were found 
in the S. griseus genome.  
As proof of concept, one cryptic pathway from Streptomyces griseus, 
SGR810-815, containing a PKS/NRPS hybrid gene, was chosen as a model system.  
BLAST search indicates that the PKS/NRPS gene shares high homology (63%) with 
the one from the heat-stable antifungal factor (HSAF) biosynthetic gene cluster (34,35) 
and 70-80% sequence homology with the recently characterized frontalamide gene 
cluster (36). Those clusters which share high homology seem to produce structurally 
similar compounds, which is called macrolide (Figure 3.1).  However, the nature of 
the natural product encoded by the target pathway is still not clear.  To decipher this 
cluster, I have been attempting to develop a new strategy based on our developed 
“DNA assembler” method.   
3.2.2 Applying the DNA assembler method to pathway assembly 
In principle, DNA assembler can be used to assemble custom-designed DNA 
fragments in any desired order by designing PCR primers to generate appropriate 
overlaps between the adjacent ones. Usually, a S. cerevisiae helper fragment carrying 
a centromere sequence (CEN), an automatic replication sequence (ARS) and a Ura+ 
selection marker, an E. coli helper fragment carrying a pBR322 ori and a Kan+ 
selection marker, and a helper fragment carrying an ori and a selection marker 
required by the desired organism, are individually prepared. These helper fragments 
are mixed with the pathway fragments, and subsequently co-transformed into S. 
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cerevisaie to be assembled into a single molecule. The transformants are selected on 
SC-Ura plates and the assembled circular DNAs are subsequently purified from S. 
cerevisiae. The isolated yeast plasmids need to be transformed to E. coli for 
enrichment and further verification. Finally, the verified plasmids can be transformed 
to the desired heterologous host for expression of the target pathway.  
First, we sought to reconstruct the original SGR810-815 biosynthetic pathway 
from S. griseus in Streptomyces lividans. To construct a shuttle system carrying the 
complete SGR810-815 gene cluster and particularly in order to minimize the possible 
mutations introduced by PCR, the biosynthetic gene cluster was split into seven 
segments with the size of ~4-5 kb each (Table 3.1). 7 pairs of primers were designed 
to cover the whole cluster according to the reported genomic sequence of S griseus 
and three pairs of primers were designed for amplification of the three helper 
fragments and generating overlap regions with the beginning and ending of the target 
cluster. The S. cerevisiae helper fragment carrying CEN6, ARS H4 and Ura3 
sequences was amplified from a yeast vector.  The E. coli helper fragment carrying 
oriR6K and accIV sequences was amplified from an E. coli vector, and accIV encodes 
for an AprR gene.  The S. lividans helper fragment carrying oriT, int, ϕ31 attP and 
tL3 sequences was amplified from the vector used for recombination with the possible 
cluster-containing fosmids in the traditional top-down approach as reported in 
literature (22).  OriT is the origin of conjugal transfer; int encodes for an integrase; 
tL3 encodes for a terminator and ϕC31 attP is the junction site for integration into the 
ϕC31 site of the chromosome. The construct is shown in Figure 3.2A. 
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Each of the fragments was individually amplified, gel purified and mixed with 
others at the end.  After precipitation in ethanol, the mixture was re-dissolved in 
ddH2O and co-transformed into S. cerevisiae through electroporation and spread onto 
SC-Ura plates. Typically, 30-50 colonies appeared after 2-3 days of incubation at 
30 °C, which were then randomly picked for plasmid isolation. 20 colonies were 
inoculated in SC-Ura liquid culture and the purified yeast plasmids were individually 
transformed to E. coli WM1788 and selected on LB-Apr+ plates. E. coli plasmids 
were subsequently purified and checked by gel electrophoresis. As a result, 18 out of 
the 20 plasmids have a relatively large size (the size of the correctly assembled 
plasmid is approximately 36 kb) while the other 2 are too small to be the desired 
plasmid. The 18 plasmids were subjected to restriction digestion by NcoI, ApaLI and 
XmnI. 13 of them exhibited an expected digestion pattern, indicating an assembly 
efficiency of 65% (Figure 3.3).   
The first three verified clones were named as pYL-#1, pYL-#7, and pYL-#18, 
respectively, and subsequently introduced into S. lividans via conjugal transfer and 
integrated into the ϕC31 site of the genome. The exconjugant integrants were verified 
by PCR and checked for potential production of a novel natural product.   
3.2.3 Product detection from the original cluster in a heterologous host 
Traditional extraction methods were applied for product detection according to 
the work flow shown in Figure 3.4. However, no product was detected from HPLC. 
Later, ammonium sulfate precipitation was performed based on the previously 
reported HSAF extraction method (34), as well as the SPE process and YMS plates 
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extraction from the frontalamide extraction method (36), but still no product was 
identified. 
3.2.4 Quantitative real-time PCR (qPCR)  
As we have confirmed that the whole cluster was correctly assembled into the 
heterologous host, the first concern was the gene expression issue. Thus, 
Revers-Transcription PCR was performed to track the gene expression. Total RNA 
was isolated based on the protocol of Total RNA Isolation Mini Kit and cDNA was 
synthesized afterwards. In parallel, to eliminate genomic DNA contamination, cDNA 
synthesis reaction without reverse transcriptase was carried out to serve as the 
negative control. Primers were designed to amplify a ~300 bp fragment for each gene 
from the cDNA library. As shown in Figure 3.5, all genes are expressed in the growth 
condition. 
In order to quantify the gene expression level, quantitative real-time PCR (qPCR) 
was employed to track the gene expression level. The hrdB gene (37), an essential 
gene of Streptomyces coelicolor A3(2), which indicates the presence of an open 
reading frame encoding a putative polypeptide of 442 amino acid (aa) residues with a 
molecular weight (Mr) of 48,412, was chosen as the internal control for all following 
qPCR experiments and its transcription signal remained comparable in all samples. 
The principal sigma-like transcriptional factor of S. coelicolor (HrdB) protein showed 
an extensive aa sequence homology with the known principal sigma factors of 
Escherichia coli, Bacillus subtilis, Pseudomonas aeruginosa and Myxococcus xanthus 
(37). The HrdB protein is the house-keeping gene in Streptomyces strains. The hrdB 
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gene in S. griseus shows high similarity to the hrdB products of Streptomyces 
coelicolor A3(2) (89.9%) and Streptomyces aureofaciens (88.1%) (38). Due to its 
stable and consistent expression level in Streptomyces strains, we chose this gene to 
serve as the internal control. Gene specific primers for genes contained in the target 
cluster were designed by Real-Time PCR tools in IDT-DNA 
(https://www.idtdna.com/scitools/Applications/RealTimePCR/). Samples were run on 
the ABI Prism 7900 HT Real-Time Quantitative PCR machine and the results were 
analyzed by SDS software. A standard curve was made first for all pair of primers 
using genomic DNA of pYL-#18 as the template. One representative example was 
shown in Figure 3.6. Real-Time PCR was performed according to a protocol 
described elsewhere (39).  
In order to obtain stable and consistent data, cells were grown for 4 days and 
samples for RNA isolation were collected at different time points, 48 h, 72 h, 96 h and 
120 h. The gene expression level from different time points were compared (Figure 
3.7). Overall, all genes were expressed after 72 h and the expression reaches its stable 
level. Therefore, 72 h was chosen as the best time point for collecting cells for total 
RNA isolation. However, we found that in the pYL-#18 construct, the expression 
levels for all genes were low and not comparable to those of the native producer- S 
griseus (SG) (Figure 3.8).  
3.2.5 Inserting the ErmE constitutive promoter 
After observing the poor gene expression levels from the qPCR results, several 
additional constructs were assembled in a similar fashion as mentioned above to help 
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facilitating the product discovery. Five different constructs were made for different 
purposes. The first one was called ErmE-1 (E1 or Ep), which contains an ErmE 
promoter in front of the whole gene cluster (Figure 3.2B). 
While in the ErmE promoter construct (E1), all genes were confirmed to be 
expressed and the first gene immediately downstream of the ErmE promoter showed a 
great increase in the gene expression level, which demonstrated that by adding 
constitutive promoters, gene expression level can be enhanced (Figure 3.8). It is 
obvious to see that by adding constitutive promoter, the expression levels of all genes 
have been improved by different extent.  
3.2.6 Promoter identification and characterization 
Based on the above results, we decided to add different constitutive promoters in 
front of each gene in the target cluster. In order to do so, a promoter library needs to 
be established. With Zengyi’s help, our lab is able to identify 10 strong constitutive 
promoters for Streptomyces strains. To search those constitutive promoters, several 
groups of housekeeping genes were targeted, such as RNA polymerase subunit α and 
β, DNA gyrase, elongation factors, RNA polymerase sigma factors, amino-acyl tRNA 
synthetase and enzymes in the essential metabolic pathways.  
From EGFP confocal microscope analysis, two promoters showed strong 
activities, gapDHp and rspLp (Figure 3.9). Based on this observation, we started to 
search similar promoters from other bacteria species. As shown on Figure 3.10, a total 
of 10 strong constitutive promoters were identified, which were used in the following 
experiments. 
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3.2.7 Creating gene expression cassettes 
As we have already confirmed that by adding constitutive promoters in front of a 
target gene would highly increase the gene expression level, we decided to add six 
different promoters in front of each gene in the cluster and this is called the fabricate 
cassettes (FC) (Figure 3.2). The first design was named AO-V1, which contains six 
different promoters in front of each gene in the cluster; the second one was named 
AO-V2, which contains three different promoters in the gap regions of the gene 
cluster; the fourth one contains 6 different promoters as well but deleted all the 
upstream and downstream genes; and the last one shares the same design as the fourth 
one, except it contains a xylE gene linked after the SGR814 gene to help track the 
protein expression level (Figure 3.2).  
We tested the gene expression levels for all those constructs by qPCR and found 
that for #7-AO-V1 in minimal medium (MM), the first gene under the GAPDH 
promoter showed a ~150 fold increase at the mRNA level. Therefore, the expression 
levels for the three AO constructs were compared in both the YMS and MM media 
(Figure 3.11). It is clear that the constructs with 6 different promoters have a higher 
mRNA levels compared to the one that only contains 3 promoters in both the YMS 
and MM media. 
The effect of medium was considered as well, since all the promoters were 
tested in the minimal medium first and the ones picked for making the AO constructs 
are the strong promoters in the minimal medium.  Because the medium we would 
prefer for production is the YMS medium, we tested the promoters’ strength in both 
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media (data not shown) and also the gene expression levels in both media (Figure 
3.12). For the two constructs chosen, AO-V1-#7 and AO-V3-#2, it is not hard to 
observe that they both expressed better in the MM than in the YMS medium, which 
indicated that the promoter picked worked better in the MM medium.  
3.2.8 Identification of final products 
We followed the product extraction method described in literature (36) to isolate 
the potential product from the target cluster. By comparing the HPLC profiles of the 
negative control (S. lividans without the target gene cluster) and the sample, a 
potential product was observed at around 24.1 min and the corresponding mass was 
(M+H): 511 (Figure 3.13 and 3.14). Further structural characterization is underway.  
3.3 Conclusions 
The strategy we developed to decipher cryptic pathways by using synthetic 
biology offers great applications in the natural product discovery area. The DNA 
assembler method we employed can be used to rapidly assemble a target gene cluster 
and heterologously express it in a desired organism.  Such a shuttle system has great 
flexibility as it is not limited by the choice of hosts as long as the corresponding 
essential elements required by the host are assembled along with the cluster.  In 
addition, such system can be used to perform targeted gene deletions, insertions, point 
mutations and replacements to facilitate the cluster mechanism studies. For example, 
if we want to understand the function of an Orf, the Orf can be removed from the 
cluster easily and the rest of the pathway will be assembled as usual.  
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In the pathway engineering experiments to help increase the production of the 
cluster, preliminary data obtained from RT-PCR indicates that all the genes are 
expressed under certain conditions. By adding different promoters in the gene cluster, 
we can detect the increase of gene expression at different levels, which proved that 
our method can be used to speed product detection.  
In order to further demonstrate the versatility of this approach and address the 
remaining questions, we plan to carry out the following experiments:  
(i) Product detection.  To determine the productivity of different constructs, all 
constructs will be grown in a series of media and potential products will be extracted. 
The most surprising feature of this cluster is the lack of additional PKS-type genes 
associated with it. This absence is particularly intriguing because if the 
PKS/NRPS-type enzymes (SGR814) were to function modularly as postulated by Yu 
et al. (34), then the enzyme’s polyketide synthase domains KS-AT-DH-KR-ACP 
would be responsible to take the malonyl group, carry out its subsequent 
decarboxylation, and incorporate into a growing polyketide backbone. Likewise, the 
C-A-T-TE NRPS domains of the PKS/NRPS enzymes should activate an ornithine 
residue and ligate it to an ACP domain-tethered polyketide before hydrolysis of the 
polyketide-peptide product from the enzyme by the TE domain. The net function of 
the PKS/NRPS enzyme would then be to elaborate a relatively small portion of the 
backbone of final compounds. This analysis led to a prediction that the complete 
HSAF cluster and frontalamide cluster would contain the additional PKS enzymes 
needed to synthesize the remainder of the polyketide chains (34,36). However, if the 
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PKS/NRPS-type enzymes function in a fashion similar to certain fungal hybrid 
PKS-NRPS enzymes, such as those involved in tenellin (40,41) and cyclopiazonic 
acid (42,43) biosynthesis, then it is not hard to understand the lack of additional PKS 
enzymes in the target cluster to produce the remainder of the polyketide backbone 
(43-45). Once we can purify the product from the heterologous expression system, we 
can prove that this cluster is complete and no additional PKS type enzyme is needed.  
(ii) Mechanism study. New constructs with deletion of genes which encodes 
modification proteins will be constructed to illustrate the cluster biosynthetic 
mechanism. If the predictions regarding the SGR814 catalysis are correct, then this 
enzyme would have a unique ability to catalyze a second round of iterative polyketide 
synthesis before condensation with the δ-amino group originating from ornithine. A 
Dieckmann cyclization would render the backbone complete, with concomitant 
product release.  However it remains unclear how the 5,5,6 polycycle of the final 
compound is formed. This biosynthetic feature will be solved once we obtain the 
SGR814’s polyketide intermediates. Therefore, we could assemble constructs 
eliminating the modification enzymes and illustrate its mechanism more clearly. (3) In 
vitro reconstitution of the SGR814 enzyme. To better understand the function of this 
enzyme, in vitro assay could be carried out to study its mechanism and kinetics. 
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3.4  Materials and methods  
3.4.1  Strains and reagents 
S. cerevisiae YSG50 (MATα, ade2-1, ade3Δ22, ura3-1, his3-11, 15, trp1-1, 
leu2-3, 112 and can1-100) was used as the host for DNA assembly and integration.  
S. lividans 66 and S. griseus were obtained from the Agricultural Research Service 
Culture Collection (Peoria, IL) and E. coli BL21 (DE3) was obtained from Novagen 
(Madison, WI).  Plasmids pAE4, E. coli strains WM6026 and WM1788 were 
developed by the Metcalf group (University of Illinois, Urbana-Champaign).  The 
pRS426 and pRS416 plasmid (New England Biolabs, Beverly, MA) were modified by 
incorporating the hisG and partial δ sequence (δ2) that flank the multiple cloning site 
and serve as the vectors for assembly of various pathways.  The resulting pRS426m 
and pRS416m were linearized by BamHI.  The δ1-hisG-ura3-hisG fragment was cut 
from pdδUB33 with BamHI and XhoI.  Plasmid pET26b(+) and pET28a(+) were 
obtained from Novagen (Madison, WI). Nalidixic acid and IPTG were obtained from 
Sigma-Aldrich (St. Louis, MO).  ISP2, agar, beef extract, yeast extract, malt extract, 
and other reagents required for cell culture were obtained from Difco (Franklin Lakes, 
NJ).  All restriction endonucleases, as well as T4 DNA ligase and antarctic 
phosphatase, were purchased from New England Biolabs (Beverly, MA).   Phusion 
DNA polymerase was from Finnzymes (Espoo, Finland).  FailsafeTM 2x premix 
buffer G was purchased from EPICENTRE Biotechnologies (Madison, WI). SYBR 
Green PCR master mix was purchased from Applied Biosystems (San Francisco, CA). 
The QIAprep Spin Plasmid Mini-prep Kit, QIAquick PCR Purification Kit, QIAquick 
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Gel Extraction Kit, and RNeasy MinElute Cleanup Kit were purchased from Qiagen 
(Valencia, CA). The Total RNA Isolation Mini Kit was obtained from Agilent 
Technologies (Santa Clara, CA). All primers were synthesized by Integrated DNA 
Technologies (Coralville, IA). 5 PRIME MasterMix was purchased from 5 PRIME 
Inc. (Gaithersburg, MD). Yeast YPAD medium-containing 1% yeast extract, 2% 
peptone and 2% dextrose supplied with 0.01% adenine hemisulphate was used to 
grow S. cerevisiae YSG50 strain.  Synthetic complete drop-out medium lacking 
uracil (SC-Ura) was used to select transformants containing the assembled 
biochemical pathways of interest. 
3.4.2 DNA manipulation 
S. griseus was grown in liquid MYG medium (4 g/L yeast extract, 10 g/L malt 
extract and 4 g/L glucose) at 30 °C with constant shaking (250 rpm) for 2 days.  The 
genomic DNA was isolated from S. griseus using the Wizard Genomic DNA isolation 
kit from Promega (Madison, WI).  Ten pairs of primers were designed with the 
sequences shown in Table 3.2.  Pathway fragments 1-SG, 2-SG, 3-SG, 4-SG, 5-SG, 
6-SG, and 7-SG were amplified from the genomic DNA of S. griseus. Generally, the 
PCRs were carried out in 100 µL reaction mixture consisting of 50 µL FailSafeTM 
PCR 2xPreMix G from Epicentre Biotechnologies (Madison, WI), 2.5 pmol of each 
primer, 1 µL yeast plasmid or genomic DNA and 2.0 unit Phusion DNA polymerase 
for 35 cycles on a PTC-200 Thermal Cycler (MJ Research, Watertown, MA).  Each 
cycle consisted of 10 s at 98 °C, 30 s at 58 °C and 3 min at 72 °C, with a final 
extension of 10 min. The S. cerevisaie helper fragment was amplified from the 
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commercial vector pRS416, while the E. coli helper fragment and the S. lividans 
helper fragment were amplified from the Streptomyces-E. coli shuttle vector pAE4.  
In order to obtain good assembly efficiency, the overlaps between the pathway 
fragments were designed to be 400 bp.  We encountered some difficulties in 
amplifying the S. cerevisaie helper fragment, and in the end, a sufficient amount of 
amplification product was only obtained by using a short pair of primers (Table 3.2).  
As a result, the S. cerevisaie helper fragment only overlaps with 7-SG and the E. coli 
helper fragment with 40 bp.  The S. lividans helper fragment has overlaps of 80 bp 
with the adjacent E. coli helper fragment and 1-SG.  Following electrophoresis, the 
PCR products were individually gel-purified from 1.0% agarose gels using Qiagen 
Gel Purification kit.  100 ng of each individual was mixed and precipitated with 
ethanol.  The resulting DNA pellet was air-dried and resuspended in 4 µL Milli-Q 
double deionized water and subsequently electroporated into S. cerevisiae using the 
protocol reported elsewhere (26).   
3.4.3 Yeast transformation 
Yeast transformation was performed by electroporation.  YPAD medium (50 
mL) was inoculated with a 0.5 mL overnight S. cerevisiae YSG50 culture and shaken 
at 30 °C and 250 rpm for 4-5 h until OD600 reached 0.8-1.0.  Yeast cells were 
harvested by centrifugation at 4 °C and 4000 rpm for 5 min.  The supernatant was 
discarded and the cell pellet was washed with 50 mL ice-cold Milli-Q 
double-deionized water, followed by another wash with cold 1 M sorbitol and finally 
resuspended in 250 µL cold sorbitol.  An aliquot of 50 µL of yeast cells together 
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with 4 µL DNA mixture was electroporated in a 0.2 cm cuvette at 1.5 kV.  The 
transformed cells were immediately mixed with 1 mL room temperature YPAD 
medium and shaken at 30 °C for 1 h.  Following that, the cells were harvested by 
centrifugation, washed with room temperature 1 M sorbitol several times to remove 
the remaining medium and finally resuspended in 1 mL sorbitol.  Aliquots of 30-50 
mL were spread on SC-Ura plates for the selection of the transformants, and the plates 
were incubated at 30 °C for 2-4 days until colonies appeared.  Colonies were 
randomly picked to SC-Ura liquid medium and grown for 1 day, after which yeast 
plasmid was isolated using Zymoprep II Yeast plasmid Miniprep kit (Zymo Research, 
CA), and genomic DNA was prepared using Wizard Genomic DNA isolation kit from 
Promega (Madison, WI). 
3.4.4 Verification of the assembled gene clusters 
Colonies were randomly picked to SC-Ura liquid media and grown for 2 day, 
after which yeast plasmid was isolated using Zymoprep II Yeast plasmid Miniprep kit 
(Zymo Research, CA).  Yeast plasmids were transformed to E. coli strain WM1788 
and selected on Luria Broth (LB) agar plates supplemented with 50 µg/ml apramycin.  
Colonies were inoculated into 5 ml of LB media supplemented with 50 µg/ml 
apramycin, and plasmids were isolated from the liquid culture using the plasmid 
miniprep kit from Qiagen.  Plasmids isolated from E. coli were then subjected to 
restriction digestion by different enzymes, after which the reaction mixtures were 
loaded to 0.7% agarose gels to check for the correct restriction digestion pattern by 
DNA electrophoresis. 
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3.4.5 Integration of the verified gene clusters onto the S. lividan 66 chromosome 
The verified constructs were transformed to E. coli WM602623 and selected on 
LB agar plates supplemented with 19 µg/mL 2,6-diaminopimelic acid and 50 µg/mL 
apramycin.  These transformants were then used as the donors for conjugal transfer 
of the assembled plasmids to S. lividans 66 following the ‘‘high-throughput’’ protocol 
described previously with the exception that the entire E. coli/S. lividans mixture was 
spotted on R2 no-sucrose media plates in 2.5 µL aliquots (46).  After incubation at 
30 °C for 16-20 hr, plates were flooded with 2 mL of a mixture of 1 mg/mL each 
nalidixic acid and Apr and incubated at 30 °C for additional 3-5 days, at which point S. 
lividans exconjugants were picked and restreaked on ISP2 plates supplemented with 
50 µg/mL nalidixic acid and 50 µg/mL Apr and allowed to grow for several days.  
These exconjugants were inoculated into the YMS medium, grown at 30 °C for 3 days 
before being spread onto YMS plates. 
3.4.6 Total RNA isolation and cDNA synthesis 
Total RNA was purified from liquid culture grown in YMS or MM for 3 days 
using the Agilent Total RNA Isolation Mini Kit according to the manufacturer’s 
instructions (City, state). Approximately 600 μL of cell lysis supernatant was used in 
each RNA purification. Total RNA was visualized by agarose gel electrophoresis and 
concentration and purity were determined using a NanoDrop (Thermo Fisher 
Scientific, Waltham, MA). Purified, concentrated total RNA was used as the template 
for cDNA synthesis using Transcriptor II reverse transcriptase enzyme (Invitrogen, 
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Carlsbad, CA) and random hexamer primer (Invitrogen, Carlsbad, CA) according to 
the manufacturer’s instructions. 
3.4.7 RT-PCR 
Experimental procedure for real-time RT-PCR using SYBR Green I was carried 
out as described elsewhere (39).  Reverse Transcription was carried out with the 
SuperScript First-Strand Synthesis System for RT-PCR. Gene specific primers for 
genes contained in my cluster were designed by Real-Time PCR tools in IDT-DNA 
(https://www.idtdna.com/scitools/Applications/RealTimePCR/). I normalized the 
primer concentrations and mixed gene-specific forward and reverse primer pair. The 
concentration of each primer in the mixture is 5 pmol/μL. The real-time PCR reaction 
mixture was set up in each optical tube. 10 μL SYBR Green Mix (2X), 1 μL cDNA, 2 
μL primer mix and 7 μl H2O were mixed gently in the optical well. I seted up the 
experiment and the following PCR program on ABI Prism 7900 HT Real-Time 
Quantitative PCR machine; 2 min at 50 °C, 10 min at 95 °C for one cycle and then 15 
s at 95 °C, 30 s at 60 °C and 30 s at 72 °C for 40 cycles with a final cycle 10 min at 
72 °C. After PCR was finished, removed the tubes from the machine and analyzed the 
real-time PCR result with the SDS software. 
3.4.8 HPLC analysis  
Streptomyces lividans contained different constructs was grown for 3 days in 15 
mL YMS liquid medium in a 125 mL shake-flask (equipped with 3 mm glass beads to 
improve liquid mixing and aeration). Aliquots (200 μL) of this seed culture were 
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spread for confluence over Petri plates containing ~25-30 mL YMS solid agar 
medium and allowed to incubate for 3-4 days at 30 °C. To isolate potential compound, 
agar and adhering cells were scraped from the plates, pooled, and covered with ethyl 
acetate to extract the products. The extract was dried under vacuum, and subsequently 
fractionated through a C18 Sepak (1 gram) SPE (solid phase extraction) column by 
eluting with a step gradient of 20%, 40%, 60%, 80%, 100% MeOH in water. The 80% 
MeOH/water fraction was subjected to further chromatography to purify potential 
products after testing individual fractions by LC/MS. Product analysis was conducted 
by comparing a series of different HPLC programs. An Agilent 1100 Series HPLC 
and ZORBAX SB-C18 reverse-phase column (3.0 x 150 mm, 3.5 μm) (Agilent 
Technologies, Palo Alto, CA) was used to monitor at 280 nm and at a flow rate of 0.5 
mL/min at 25 °C. A gradient of 10-100% acetonitrile in water with 0.1% formic acid 
over 20 min was used and data were collected using a diode array to monitor 
absorbance at 280 nm. Mass spectral data were acquired using ESI-MS on an Agilent 
6130 Series mass spectrometer, where both positive and negative ions were 
monitored.  
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Figure 3.2 Six different constructs assembled by DNA assembler. A: the original construct 
from S griseus and heterologous constructed in S lividans, several upstream and downstream 
genes are included to maintain the potential regulation of the gene cluster. B: The ErmE 
promoter was inserted in front of the whole gene cluster SGR910-815. C: Three different 
promoters in the gap of the gene cluster. D: Gene cluster contains six different promoters in 
front of each gene. E: Gene cluster contains six different stronger promoters in front of each 
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gene, and deleted all the upstream and downstream genes. F: Gene cluster contains six 
different stronger promoters in front of each gene, and deleted all the upstream and 
downstream genes. Also, a XylE gene was linked to the end of the SGR814 gene.  
 
 
Figure 3.3 Physical characterization of the recombinant clones through restriction digestion.  
Plasmids were digested by NcoI, XmnI and ApalI.  The correct clones were marked as the 
red stars. 
 
 
Figure 3.4 Sample preparation work flow 
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#18 Construct 
L     810     811     812    813     815         L       814(-)                     814(+) 
  
 
Figure 3.5 Reverse-Transcription PCR results. The left figure: on the top of the figure, the 
results showed that the genes in #18 constructs were all expressed except 814. The bottom 
part is the negative controls. The right figure showed the gene 814 was expressed when 
compared with the negative control. 
 
 
Figure 3.6 One example of the standard curve made for Real-Time-PCR. pYL-#18 genomic 
DNA was used as the PCR template, which was diluted to 100,1000, 10000 and 100000 
times.  
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Figure 3.7 Different time points real-time PCR results. 1: #18 120h, 2: #18 72h, 3:#18 96h, 
4:E1 120h, 5: E1 72h, 6: E1 96h, 7: SG: 120h, 8:SG 48h, 9:SG 72h, 10: SG 96h 
 
 
Figure 3.8 Comparison of the gene expression level of different constructs. HrdB was used as 
internal control, whose expression level was set as 1. OC: original construct; SG: S. griseus 
(native producer); Ep: ErmE promoter added in front of the whole gene cluster; FC: 
Expression cassette (different promoters in front of each gene in the cluster). 
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Figure 3.9 EGFP confocal microscope results identified two strong promoters: gaDHp and 
rpsLp from S. griseus. 
 
 
Figure 3.10 EGFP confocal microscope results for promoters: gaDHp and rpsLp from other 
species. 
 
 
Figure 3.11 Comparison of the gene expression levels of AO v1(#7), AO v2（2-6）, and AO 
v3 (3-2 and 3-4in both YMS medium and minimal medium. 
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Figure 3.12 Comparison of the same construct’s gene expression levels in both YMS medium 
and minimal medium. 
 
 
Figure 3.13 HPLC analysis of the negative control and the sample.  
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Figure 3.14 MS1 and MS2 data of the identified new potential product peak.  
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Table 3.1 Fragments size and region located on the genomic DNA of S griseus. 
Fragments Primers Size Region 
1 1-for 5635 2501-8135 
 1-rev   
2 2-for 4479 7716-12194 
 2-rev   
3 3-for 5226 11775-17000 
 3-rev   
4 4-for 5220 16581-21800 
 4-rev   
5 5-for 4810 21381-26190 
 5-rev   
6 6-for 3048 25771-28818 
 6-rev   
7 7-for 4141 28381-32521 
 7-rev   
Yeast fragment Yeast-for 1859 32522-34380 
 Yeast-rev   
E. coli fragment E.coli-for 1430 34381-35810 
 E. coli-rev   
Streptomyces fragment Strep-for 3353 35811-2500 
 Strep-rev   
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Table 3.2 Primers designed to amplify each gene from the genomic DNA of S griseus. 
Amplified fragment Primer sequence (5’->3’) 
1-SG gtagaaacagacgaagaagctagctttgcactggattgcg gtgggtcctttcgggtcgac 
 gaaccgtccacgactggtga 
2-SG ttcaacacggtgtacgacta 
 cctgtcctgtcgccgctcac 
3-SG cttccgtacgaggcgggcgt 
 Tgcagcaggaggtagtacgc 
4-SG gaagcggccctcggcctcgt 
 gcgcgcgaggtgtaggcgac 
5-SG cgccgcgtggaaggcggcga 
 actggctgcgacaggggtga 
6-SG gggacccgcgccgcggtgga 
 gttaccgatcgggtattcat 
7-SG ggactgctggtccgacgatc 
 ccagggcccagatgacgaagcgaaaagtgccacctgggtccttttcatcacgtgctataa 
S. cerevisaie helper fragment cgaaaagtgccacctgggtc 
 gtgagtttagtatacatgca 
E. coli helper fragment aaaactgtattataagtaaatgcatgtatactaaactcactgtcatcacgatactgtgat 
 tttcagcgtgacatcattctgtgggccgtacgctggtactgcaaatacggcatcagttac 
S. lividans helper fragment acccattcaaaggccggcattttcagcgtgacatcattctgtgggccgtacgctggtact 
 tagctttgcactggattgcg gtgggtcctttcgggtcgacggctcgtcgcagtatcgcgg 
 
 
 
